A sequence graph-based tool for determining variation in short tandem repeat regions

By employing sequence graphs and paired-end sequencing, the method addresses alignment challenges in repetitive sequences, enabling precise detection and quantification of repeat expansions in genomic sequences.

JP7581191B2Active Publication Date: 2024-11-12ILLUMINA INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021518136
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-03-07
Filing Date
2020-03-06
Publication Date
2024-11-12
Estimated Expiration
2040-03-06

AI Technical Summary

Technical Problem

Current methods struggle to accurately identify and quantify repeat expansions in genomic sequences using short reads, as they often fail to completely traverse repetitive sequences, leading to alignment ambiguities and errors, especially in complex loci with multiple repeats.

Method used

The use of sequence graphs, which are directed graphs with self-loops representing repeating subsequences, allows for the alignment and genotyping of repetitive sequences by aligning sequence reads into these graphs, incorporating techniques like paired-end sequencing and probabilistic modeling to determine genotypes.

Benefits of technology

This approach enables accurate detection and quantification of repeat expansions, even with short reads, improving sensitivity and selectivity in identifying medically relevant expansions associated with genetic diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007581191000002
    Figure 0007581191000002
  • Figure 0007581191000003
    Figure 0007581191000003
  • Figure 0007581191000004
    Figure 0007581191000004
Patent Text Reader

Abstract

Disclosed embodiments relate to methods, devices, systems, and computer program products for genotyping repetitive sequences, such as medically significant short tandem repeats (STRs). The methods include aligning reads to a repetitive sequence represented by a sequence graph and genotyping the repetitive sequence using the aligned reads. The sequence graphs are directed graphs, each including at least one self-loop representing a repetitive subsequence. In some embodiments, the reads are paired-end reads, and both mates of each read pair may be used to genotype the repetitive sequence. Some embodiments can be used to determine degenerate codon repeats. Some embodiments can be used to genotype repetitive sequences that each contain two or more repetitive subsequences. Some embodiments can be used to genotype nucleic acid sequences that each contain at least one repetitive subsequence and another genetic variant, such as an insertion, deletion, or substitution.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] (Incorporated by reference) The PCT application form is filed contemporaneously herewith as a part of this application. Each application to which this application claims the benefit or priority of any identified in the contemporaneously filed PCT application form is hereby incorporated by reference in its entirety. [Background technology]

[0002] Repeat expansion is a special class of microsatellite and minisatellite variants, including short tandem repeat (STR) polymorphisms. Repeat expansion is also known as dynamic mutation due to the instability of short tandem repeats when they expand beyond a certain size. Genetic diseases caused by unstable repeat expansion include Fragile X Syndrome (FXS), Huntington's disease, and amyotrophic lateral sclerosis (ALS), among others.

[0003] Identifying repeat expansions is important in the diagnosis and treatment of certain genetic diseases. However, it is difficult to determine repeat sequences using short reads that do not completely traverse the repeat sequence. Therefore, it is desirable to develop methods that use short reads to identify medically relevant repeat expansions. Summary of the Invention

[0004] Disclosed embodiments relate to methods, devices, systems, and computer program products for sequencing genomic loci that contain repetitive sequences, such as short tandem repeat sequences, that may be associated with genetic disease. The methods include aligning reads to a sequence graph, each of which represents a genomic locus, and genotyping one or more repetitive sequences at the genomic locus using the aligned reads. The sequence graphs are directed graphs that each include at least one self-loop that represents the repetitive sequence.

[0005] A first aspect of the present disclosure provides a computer-implemented method for genotyping genomic loci that include repetitive sequences. The method is executed using a computer that includes one or more processors and a system memory. The method can be used to genotype one or more repetitive sequences that each include one or more repetitive subsequences. The method includes: (a) collecting sequence reads of a test sample from a database using one or more processors; (b) aligning the sequence reads by the one or more processors to one or more repetitive sequences, each represented by a sequence graph, the sequence graph having a data structure of a directed graph with vertices representing nucleic acid sequences and directed edges connecting the vertices, the sequence graph including one or more self-loops, each self-loop representing a repetitive subsequence, each repetitive subsequence including repeats of one or more nucleotide repeat units; and (c) determining, by the one or more processors, one or more genotypes for the one or more repetitive sequences using the sequence reads aligned to the one or more repetitive sequences.

[0006] In some embodiments, a repeat sequence of the one or more repeat sequences comprises a specific repeat unit that comprises at least one incompletely specified nucleotide, hi some embodiments, the specific repeat unit comprises a degenerate codon.

[0007] In some embodiments, the one or more self-loops include two or more self-loops representing two or more repeated subsequences.

[0008] In some embodiments, the sequence graph further comprises two or more alternative pathways for the two or more alleles. In some embodiments, the two or more alleles comprise indels or substitutions. In some embodiments, the substitutions comprise single nucleotide variants (SNVs) or single nucleotide polymorphisms (SNPs). In some embodiments, the method further comprises genotyping the two or more alleles using sequence reads aligned to the two or more alternative pathways. In some embodiments, genotyping the two or more alleles comprises providing coverage of the two or more alternative pathways to a probabilistic model to determine the probability of the two or more alleles. In some embodiments, the probabilistic model simulates the probability of the allele as a function of coverage of the allele, where the function is selected from a Poisson distribution, a negative binomial distribution, a binomial distribution, or a beta-binomial distribution. In some embodiments, the rate parameters of the Poisson distribution are estimated from the read lengths and average depths observed at the genomic loci.

[0009] In some embodiments, the method further comprises, prior to (b), aligning the sequence reads to a reference genome to determine genomic coordinates of the sequence reads, and selecting a subset of the sequence reads as sequence reads that each align with one or more repeat sequences represented by the sequence graph. In some embodiments, the subset of sequence reads includes reads that align to or near the region represented by the sequence graph. In some embodiments, the subset of sequence reads includes unaligned reads that map to or near the region represented by the sequence graph. In some embodiments, the subset of sequence reads includes reads that align to one or more off-target regions that are known hotspots for misaligning reads.

[0010] In some embodiments, aligning the sequence reads to the sequence graph includes finding a kmer match between the sequence reads and paths in the sequence graph, and extending the kmer match to a complete alignment of nodes and edges of the sequence graph, including one or more self-loops.

[0011] In some embodiments, aligning sequence reads to a sequence graph includes reducing the graph by eliminating results with low confidence in the alignment.

[0012] In some embodiments, aligning the sequence reads to the sequence graph comprises aligning subsequences of the reads to the sequence graph and merging the sequences of the subsequences to form a complete sequence of the sequence read.

[0013] In some embodiments, the method further comprises generating a sequence graph based on the locus specification that includes a locus structure of the genomic locus.

[0014] In some embodiments, the sequence reads include paired-end reads, and operation (c) includes (i) identifying an anchor read and an anchored read within the paired-end reads, where the anchor read aligns to or aligns near the one or more repetitive sequences, and the anchored read is a non-aligned read paired with the anchor read, and (ii) determining one or more genotypes for the one or more repetitive sequences using at least the anchored read.

[0015] In some embodiments, operation (ii) comprises determining one or more genotypes for one or more repeat sequences using the anchored reads and the anchored reads. In some embodiments, the anchored reads are aligned within about 5 kb of the repeat sequence. In some embodiments, the unaligned reads comprise reads that cannot be aligned to the sequence graph or that are poorly aligned to the sequence graph.

[0016] In some embodiments, the one or more repeat sequences comprise short tandem repeat (STR) sequences, in which STR expansions are associated with fragile X syndrome, amyotrophic lateral sclerosis (ALS), Huntington's disease, Friedreich's ataxia, spinocerebellar degeneration, spinal-bulbar muscular atrophy, myotonic dystrophy, Machado-Joseph disease, or dentatorubral-pallidoluysian atrophy.

[0017] In some embodiments, the method further includes generating paired-end reads from the test sample using a sequencer.

[0018] In some embodiments, the method further comprises extracting a test sample from the individual.

[0019] In some embodiments, the test sample is a blood sample, a urine sample, a saliva sample, or a tissue sample.

[0020] In some embodiments, the repeat unit comprises 1-50 nucleotides.

[0021] In some embodiments, the read is shorter than at least one of the one or more repeat sequences.

[0022] Another aspect of the present disclosure provides a system for genotyping genomic loci that include repetitive sequences. In some embodiments, the system includes a system memory and one or more processors configured to (a) collect sequence reads of a test sample from a database using one or more processors, (b) align, by the one or more processors, the sequence reads to one or more repetitive sequences, each represented by a sequence graph, the sequence graph having a directed graph data structure with vertices representing nucleic acid sequences and directed edges connecting the vertices, the sequence graph including one or more self-loops, each self-loop representing a repetitive subsequence, each repetitive subsequence including repeats of one or more nucleotide repeat units, and (c) determine, by the one or more processors, one or more genotypes for the one or more repetitive sequences using the sequence reads aligned to the one or more repetitive sequences.

[0023] In some embodiments, the system also includes a sequencer for sequencing nucleic acids of the test sample.

[0024] In some embodiments, one or more processors are configured to perform the various methods described herein.

[0025] Another aspect of the present disclosure provides a computer program product including a non-transitory machine-readable medium storing program code that, when executed by one or more processors of a computer system, causes the computer system to perform the above-described method for genotyping genomic loci that contain repetitive sequences, the program code including: (a) code for collecting sequence reads of a test sample from a database, (b) code for aligning the sequence reads to one or more repetitive sequences, each represented by a sequence graph, the sequence graph having a directed graph data structure with vertices representing nucleic acid sequences and directed edges connecting the vertices, the sequence graph including one or more self-loops, each self-loop representing a repetitive subsequence, each repetitive subsequence including repeats of one or more nucleotide repeat units, and (c) code for determining one or more genotypes for the one or more repetitive sequences using the sequence reads aligned to the one or more repetitive sequences.

[0026] In some embodiments the program code comprises code for performing operations of the methods described herein.

[0027] Although the examples herein relate to humans and the language is directed primarily to humans, the concepts described herein are applicable to genomes from any plant or animal. These and other objects and features of the present disclosure will become more fully apparent from the following description and appended claims, or may be learned by the practice of the present disclosure as set forth hereinafter. [Brief description of the drawings]

[0028] [Figure 1A] FIG. 1 is a schematic showing the difficulties in aligning sequence reads to repetitive sequences on a reference sequence. [Figure 1B] FIG. 1B is a schematic diagram showing alignment of sequence reads using paired-end reads, in accordance with certain disclosed embodiments, to overcome the difficulties depicted in FIG. 1A. [Figure 1C]1 shows a flowchart illustrating a process for genotyping genomic loci that contain repetitive sequences according to some embodiments. [Figure 1D] 1 shows a first sequence graph representing a first genomic locus. [Figure 1E] 1 shows a second sequence graph representing a second genomic locus. [Figure 1F] 1 shows a third sequence graph representing a third genome. [Figure 1G] FIG. 1 shows a schematic diagram of a process for genotyping a variant in HTT comprising two STR sequences, according to some embodiments. [Figure 1H] FIG. 1H shows a schematic of a process for genotyping variants at the Lynch I locus, including SNVs and STRs, according to some embodiments. The left panel of FIG. 1H shows a schematic of the general process for targeted genotyping, and the right panel shows application of this process to genotyping variants at a locus associated with Lynch I syndrome. [Diagram 2] FIG. 1 is a flow diagram providing a high-level depiction of an example of a method for determining the presence or absence of a repeat sequence expansion in a sample. [Diagram 3] FIG. 1 is a flow diagram showing an example of a method for detecting repeat expansions using paired-end reads. [Figure 4] FIG. 1 is a flow diagram showing an example of a method for detecting repeat expansions using paired-end reads. [Diagram 5] FIG. 1 is a flow diagram of a method for using unaligned reads that are not related to any repetitive sequence of interest to determine repeat expansions. [Figure 6] FIG. 1 is a block diagram of a distributed system for processing samples for testing. [Figure 7] We demonstrate the accuracy of genotyping the CAG and CCG STRs at the HTT locus using different methods. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0029] The present disclosure relates to methods, devices, systems, and computer program products for identifying repeat expansions of interest, such as expansions of repetitive sequences that are medically significant, including, but not limited to, expansions associated with genetic diseases such as Fragile X Syndrome, ALS, Huntington's Disease, Friedreich's Ataxia, Spinocerebellar Degeneration, Spinobulbar Muscular Atrophy, Myotonic Dystrophy, Machado-Joseph Disease, and Dentatorubral-Pallidoluysian Atrophy.

[0030] Unless otherwise indicated, practice of the methods and systems disclosed herein involves conventional techniques and equipment commonly used in molecular biology, microbiology, protein purification, protein engineering, protein and DNA sequencing, and recombinant DNA fields that are within the skill of the art. Such techniques and equipment are known to those of skill in the art and are described in numerous texts and reference works (see, for example, Sambrook et al., "Molecular Cloning: A Laboratory Manual," Third Edition (Cold Spring Harbor),

[2001] , and Ausubel et al., "Current Protocols in Molecular Biology,"

[1987] ).

[0031] Numeric ranges are inclusive of the numbers defining the range. Every maximum numerical limitation given throughout this specification is intended to include every lower numerical limitation, as if such lower numerical limitation were expressly written herein. Every minimum numerical limitation given throughout this specification includes every higher numerical limitation, as if such higher numerical limitations were expressly written herein. Every numerical range given throughout this specification includes every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein.

[0032] The headings provided herein are not intended to limit the disclosure.

[0033] Unless otherwise defined herein, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art.Various scientific dictionaries, including the terms contained herein, are known and available in the art.It has been found that any method and material similar or equivalent to those described herein can be used to carry out or test the embodiments disclosed herein, but some methods and materials are described.

[0034] The terms defined below are more fully described by reference to the specification as a whole. It is understood that this disclosure is not limited to the particular methodology, protocols, and reagents described, as these may vary depending on the context in which they are used by those of skill in the art. definition

[0035] As used herein, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise.

[0036] Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively.

[0037] The term "plurality" refers to two or more elements, e.g., the term is used herein in reference to a large number of nucleic acid molecules or sequence reads sufficient to identify significant differences in repeat expansions in test and control samples using the methods disclosed herein.

[0038] The term "repetitive sequence" refers to a nucleic acid sequence that contains repeated occurrences of shorter sequences. The shorter sequences are referred to herein as "repeat units". The repeated occurrences of the repeat units are referred to as "repeats" or "duplications" of the repeat units. In many contexts, the location of the repeat sequence is associated with a gene that codes for a protein. In other situations, the repeat sequence may be in a non-coding region. The repeat units may occur in the repeat sequence with or without breaks between the repeat units. For example, in normal samples, the FMR1 gene tends to contain AGG breaks in the CGG repeats, e.g., (CGG)10+(AGG)+(CGG)9. Samples that do not contain breaks, as well as long repeat sequences with some breaks, are prone to repeat expansions of the associated genes, which may lead to genetic diseases when the repeats are expanded beyond a certain number. In various embodiments of the present disclosure, the number of repeats is counted as in-frame repeats, regardless of breaks. Methods for estimating in-frame repeats are further described below.

[0039] In various embodiments, the repeat unit comprises 1-100 nucleotides. Many repeat units that have been widely studied are trinucleotide or hexannucleotide units. Some other repeat units that have been well studied and are applicable to the embodiments disclosed herein include, but are not limited to, 4, 5, 6, 8, 12, 33 or 42 nucleotide units. See, for example, Richards (2001) Human Molecular Genetics, 10, No. 20, 2187-2194. The application of the present disclosure is not limited to the above specific number of nucleotide bases, as long as they are relatively short compared to repetitive sequences that have multiple repeats or copies of the repeat unit. For example, the repeat unit can comprise at least 3, 6, 8, 10, 15, 20, 30, 40, 50 nucleotides. Alternatively or additionally, the repeat unit can comprise up to about 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 6 or 3 nucleotides.

[0040] Repetitive sequences can expand under evolutionary, developmental, and mutational conditions, creating more copies of the same repeat unit. This is referred to within the field as "repeat expansion." This process is also referred to as "dynamic mutation" due to the unstable nature of the repeat unit expansion. Some repeat expansions have been shown to be associated with genetic diseases and pathological conditions. Other repeat expansions are not as well understood or studied. Using the methods disclosed herein, both known and novel repeat expansions can be identified. In some embodiments, the repetitive sequence having a repeat expansion is longer than about 100, 150, 300, or 500 base pairs (bp). In some embodiments, the repetitive sequence having a repeat expansion is longer than about 1000 bp, 2000 bp, 3000 bp, 4000 bp, 5000 bp, or 10000 bp, etc.

[0041] In graph theory, vertices and edges are the two basic units on which graphs are constructed. A vertex or node is one of the points at which a graph is defined and may be connected by edges. In a graph diagram, vertices may be represented by shapes with labels, and edges are represented by lines (undirected edges) or arrows (directed edges) that extend from one vertex to another.

[0042] Two vertices connected by an edge are said to be the endpoints of the edge. A vertex x is said to be adjacent to another vertex y if the graph contains an edge (x, y).

[0043] An untargeted graph consists of a set of vertices and a set of undirected edges (connecting pairs of non-regular vertices), while a directed graph consists of a set of vertices and a set of directed edges (connecting pairs of regular vertices).

[0044] In graph theory, each edge has two (or more in hypergraphs) vertices attached to it, called its endpoints. Edges may be directed or undirected. Undirected edges are also called lines, and directed edges are also called arcs or arrows.

[0045] A directed edge is an edge that connects an upstream vertex and a downstream vertex, where the upstream vertex occurs before the directed edge and the downstream vertex occurs after the directed edge.

[0046] An uncovered edge is an edge that connects two vertices, either of which may appear before the other in a graph path.

[0047] Loop, self-loop, and single-node loop are used interchangeably herein. A loop has one node and an end connected at both ends to a single node.

[0048] A cycle is a path that contains two or more vertices, where the paths of a cycle start and end at the same vertex. A simple cycle is a cycle that has no repeated vertices or edges other than the starting and ending vertices.

[0049] A cyclic graph is a graph that contains at least one cycle.

[0050] An acyclic graph is a graph that does not contain any cycles or self-loops.

[0051] Acyclic graphs (DAGs) of interest are directed graphs that do not contain any cycles or self-loops.

[0052] A graph path is an array of vertices and edges, where both endpoints of an edge occur adjacent to the edges in the array. A graph path in a directed graph has upstream vertices that occur before the directed edge (or arc or arrow), and downstream vertices that occur after the directed edge.

[0053] The Poisson distribution is a discrete probability distribution that represents the probability of a given number of events occurring in a fixed time or space interval, when these events occur at a known constant rate and are independent of the time since the last event.

[0054] Fully specified base symbols include G, A, T, C for guanine, adenine, thymine, and cytosine.

[0055] Non-fully specified nucleic acid nomenclature includes, among others, the following:

[0056] Purine (adenine or guanine): R

[0057] Pyrimidine (thymine or cytosine): Y

[0058] Adenine or thymine: W

[0059] Guanine or cytosine: S

[0060] Adenine or cytosine: M

[0061] Guanine or thymine: K

[0062] Adenine or Thymine or Cytosine: H

[0063] Guanine or cytosine or thymine: B

[0064] Guanine or adenine or cytosine: V

[0065] Guanine or adenine or thymine: D

[0066] Guanine or adenine or thymine or cytosine: N

[0067] The term "paired end reads" refers to reads obtained from paired end sequencing, which obtains one read from each end of a nucleic acid fragment. Paired end sequencing involves fragmenting DNA into sequences, called inserts. In some protocols used by Illumina, reads from shorter inserts (e.g., about 10 to several hundred bp) are referred to as short-insert paired-end reads, or simply paired-end reads. In contrast, reads from longer inserts (e.g., about several thousand bp) are referred to as mate pair reads. In this disclosure, both short-insert paired-end reads and long-insert mate pair reads may be used and are not differentiated with respect to the process for analyzing repeat extensions. Thus, the term "paired end read" may refer to both short-insert paired-end reads and long-insert mate pair reads, which are described further below in this specification. In some embodiments, the paired-end reads include reads of about 20 bp to 1000 bp. In some embodiments, the paired-end reads include reads of about 50 bp to 500 bp, about 80 bp to 150 bp, or about 100 bp. It will be understood that the two reads of a paired end need not be located at the very ends of the fragment being sequenced. Rather, one or both reads can be proximate to the ends of the fragment. Additionally, the methods exemplified herein in the context of paired-end reads can be performed with any of a variety of paired reads, regardless of whether the reads are derived from the ends of the fragment or other portions of the fragment.

[0068] As used herein, the terms "alignment" and "aligned" refer to a process of comparing a read to a reference sequence, thereby determining whether the reference sequence contains the read sequence. The alignment process seeks to determine whether the read can be mapped to the reference sequence, but does not always align the read to the reference sequence. If the reference sequence contains the read, the read may be mapped to the reference sequence, or in certain alternative embodiments, may be mapped to a particular location within the reference sequence. In some cases, alignment simply tells whether the read is a member of a particular reference sequence (i.e., whether the read is present or absent in the reference sequence). For example, alignment of a read to a reference sequence for human chromosome 13 tells whether the read is present in the reference sequence for chromosome 13. Tools that provide this information may be referred to as set membership testers. In some cases, alignment also indicates the location within the reference sequence to which the read maps. For example, if the reference sequence is the entire human genome sequence, alignment may indicate that the read is present on chromosome 13, and may further indicate that the read is on a particular strand and / or site of chromosome 13.

[0069] An aligned read is one or more sequences that are identified as being aligned with respect to the order of their nucleic acid molecules relative to a known reference sequence, such as a reference genome. The aligned reads and their determined positions on the reference sequence constitute a sequence tag. Alignment can be performed manually, but is typically performed by a computer algorithm, since it is not possible to align the reads in a reasonable time period to perform the methods disclosed herein. One example of an algorithm for aligning sequences is the Efficient Local Alignment of Distributed Nucleotide Data (ELAND) computer program as part of the Illumina Genomics Analysis pipeline. Alternatively, a Bloom filter or similar set membership tester can be used to align the reads to the reference genome. See U.S. Patent Application No. 14 / 354,528, filed April 25, 2014, which is incorporated herein by reference in its entirety. The alignment of sequence reads can be 100% sequence alignment, or less than 100% alignment (i.e., not perfect alignment).

[0070] The term "mapping" as used herein means assigning a read sequence to a larger sequence, e.g., a reference genome, by alignment.

[0071] In some cases, one end read of the two paired-end reads is aligned to a repeat sequence of the reference sequence, while the other end read of the two paired-end reads is not aligned. In such cases, the paired read aligned to the repeat sequence of the reference sequence is called an "anchor read". A paired-end read that is not aligned to a repeat sequence but is paired with an anchor read is called an anchored read. Thus, a non-aligned read may be anchored to a repeat sequence and associated with a repeat sequence. In some embodiments, a non-aligned read includes both a read that cannot be aligned to a reference sequence and a read that is poorly aligned to a reference sequence. A read is considered to be poorly aligned if it is aligned to a reference sequence with more mismatched bases than a certain criterion. For example, in various embodiments, a read is considered to be poorly aligned if it is aligned with at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mismatches. In some cases, both paired reads are aligned to a reference sequence. In such cases, in various embodiments, both reads may be analyzed as "anchor reads".

[0072] The terms "polynucleotide", "nucleic acid", and "nucleic acid molecule" are used interchangeably to refer to a covalently linked sequence of nucleotides (i.e., ribonucleotides for RNA and deoxyribonucleotides for DNA) in which the 3' position of the pentose of one nucleotide is linked to the 5' position of the next pentose by a phosphodiester group. Nucleotides include sequences of any form of nucleic acid, including, but not limited to, RNA molecules and DNA molecules such as cell-free DNA (cfDNA) molecules. The term "polynucleotide" includes, but is not limited to, single-stranded and double-stranded polynucleotides.

[0073] As used herein, the term "test sample" refers to a sample derived from a biological fluid, cell, tissue, organ, or organism that contains a nucleic acid or mixture of nucleic acids having at least one nucleic acid sequence to be evaluated for copy number variation. In certain embodiments, the sample has at least one nucleic acid sequence whose copy number is likely to be mutated. Such samples include, but are not limited to, sputum / oral fluid, amniotic fluid, blood, blood fractions, or fine needle biopsy samples, urine, peritoneal fluid, pleural fluid, and the like. Samples are often taken from human subjects (e.g., patients), but the assay can be used for copy number variation (CNV) in any mammalian sample, including, but not limited to, canine, feline, equine, caprine, ovine, bovine, porcine, and the like. Samples may be used directly as obtained from a biological source or after pretreatment to modify the characteristics of the sample. For example, such pretreatment may include preparing plasma from blood, diluting viscous fluids, and the like. Pretreatment methods may include, but are not limited to, filtration, precipitation, dilution, distillation, mixing, centrifugation, freezing, lyophilization, concentration, amplification, nucleic acid fragmentation, inactivation of interfering components, addition of reagents, lysis, etc. When such pretreatment methods are employed on a sample, such pretreatment methods are typically such that the nucleic acid(s) of interest remain in the test sample, sometimes at a concentration proportional to the untreated test sample (e.g., a sample that has not been subjected to any such pretreatment method(s)). Such "treated" or "processed" samples are still considered to be biological "test" samples with respect to the methods described herein.

[0074] The control sample may be a negative control sample or a positive control sample. A "negative control sample" or "unaffected sample" refers to a sample containing a nucleic acid that is known or expected to have a repetitive sequence with a number of repeats in a non-pathogenic range. A "positive control sample" or "affected sample" refers to a sample containing a nucleic acid that is known or expected to have a repetitive sequence with a number of repeats in a pathogenic range. The repeats of the repetitive sequence in the negative control sample are not usually extended beyond the normal range, while the repeats of the repetitive sequence in the positive control sample are usually extended beyond the normal range. Thus, the nucleic acid in the test sample can be compared to one or more control samples.

[0075] The term "sequence of interest" as used herein refers to a nucleic acid sequence that is associated with differences in sequence expression in healthy versus diseased individuals. A sequence of interest may be a repetitive sequence on a chromosome that is expanded in a disease or genetic condition. A sequence of interest may be part of a chromosome, a gene, a coding or non-coding sequence.

[0076] As used herein, the term "next-generation sequencing (NGS)" refers to sequencing methods that allow for massively parallel sequencing of clonally amplified molecules and single nucleic acid molecules. Non-limiting examples of NGS include sequencing-by-synthesis using reversible dye terminators and sequencing-by-ligation.

[0077] As used herein, the term "parameter" refers to a numerical value that characterizes a physical property. Often, a parameter numerically characterizes a quantitative data set and / or a numerical relationship between quantitative data sets. For example, the ratio (or a function of the ratio) between the number of sequence tags located on a chromosome and the length of the chromosome to which the tags are mapped is a parameter.

[0078] As used herein, the term "call criterion" refers to any number or amount used as a cutoff to characterize a sample, such as a test sample, containing nucleic acid from an organism suspected of having a medical condition. The threshold may be compared to the parameter value to determine whether a sample giving rise to such a parameter value indicates that the organism has a medical condition. In certain embodiments, the threshold is calculated using a control data set and serves as a diagnostic limit for repeat expansion in the organism. In some embodiments, if the threshold is exceeded by the results obtained from the methods disclosed herein, the subject may be diagnosed with a repeat expansion. An appropriate threshold for the methods described herein may be identified by analyzing values ​​calculated for a training set of samples or control samples. The threshold may also be calculated from empirical parameters such as sequencing depth, read length, repeat sequence length, etc. Alternatively, affected samples known to have repeat expansions may be used to confirm that the selected threshold is useful in distinguishing affected samples from unaffected samples in the test set. The choice of threshold depends on the confidence with which the user desires to make the classification. In some embodiments, the training set used to identify an appropriate threshold value includes at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 2000, at least 3000, at least 4000, or more qualified samples. It may be advantageous to use a larger set of qualified samples to improve the diagnostic utility of the threshold value.

[0079] The term "read" refers to a sequence read from a portion of a nucleic acid sample. Typically, but not necessarily, a read represents a short sequence of consecutive base pairs in a sample. A read may be symbolically represented by the base pair sequence (ATCG) of the sample portion. A read may be stored in a memory device and appropriately processed to determine whether the read matches a reference sequence or meets other criteria. A read may be obtained directly from a sequencing device or indirectly from stored sequence information about the sample. In some cases, the DNA sequence is of sufficient length (e.g., at least about 25 bp) that it can be used to identify a larger sequence or region, which can be aligned and located, for example, to a chromosome or genomic region or gene.

[0080] The term "genomic read" is used in reference to a read of any segment in an individual's entire genome.

[0081] The term "site" refers to a unique location on a reference genome (e.g., chromosome ID, chromosomal location and orientation). In some embodiments, a site may be a residue, a sequence tag, or the location of a segment on a sequence.

[0082] As used herein, the term "reference genome" or "reference sequence" refers to a specific known genomic sequence, either partial or complete, of any organism or virus that can be used to reference a specified sequence from a subject. For example, reference genomes used for human subjects, as well as many other organisms, can be found at the National Center for Biotechnology Information at ncbi.nlm.nih.gov. "Genome" refers to the complete genetic information of an organism or virus, expressed in a nucleic acid sequence.

[0083] In various embodiments, a reference sequence may be significantly larger than the reads aligned to it. For example, it may be at least about 100 times larger, or at least about 1000 times larger, or at least about 10,000 times larger, or at least about 10 5times larger, or at least about 10 6 times larger, or at least about 10 7 It may be twice as large.

[0084] In one example, the reference sequence is of the full-length human genome. Such sequences are sometimes referred to as genomic reference sequences. In another example, the reference sequence is limited to a particular human chromosome, such as chromosome 13. In some embodiments, the reference Y chromosome is a Y chromosome sequence from human genome version hg19. Such sequences are sometimes referred to as chromosome reference sequences. Other examples of reference sequences include genomes of other species, as well as chromosomes of any species, partial chromosomal regions (strands, etc.), etc.

[0085] In some embodiments, the reference sequence for alignment may have a sequence length of about 1 to about 100 times the length of the read. In such embodiments, the alignment and sequencing is considered as targeted alignment or sequencing instead of whole genome alignment or sequencing. In these embodiments, the reference sequence typically includes the gene and / or repeat sequence of interest.

[0086] In various embodiments, the reference sequence is a consensus sequence or other combination from multiple individuals, although in certain applications the reference sequence may be taken from a specific individual.

[0087] As used herein, the term "clinically relevant sequence" refers to a nucleic acid sequence that is known or suspected to be associated with or implicated in a genetic or medical condition. Determining the absence or presence of a clinically relevant sequence can be useful in determining a diagnosis or confirming a diagnosis of a medical condition or providing a prognosis for the development of a disease.

[0088] The term "derived" as used herein in the context of a nucleic acid or mixture of nucleic acids refers to the means by which the nucleic acid(s) are obtained from the source from which the nucleic acid originates. For example, in one embodiment, a mixture of nucleic acids derived from two different genomes means that the nucleic acids, e.g., cfDNA, are naturally released by cells through naturally occurring processes such as necrosis or apoptosis. In another embodiment, a mixture of nucleic acids derived from two different genomes means that the nucleic acids are extracted from two different types of cells from a subject.

[0089] The term "based on" when used in the context of deriving a particular quantitative value means using another quantity as an input to calculate the particular quantitative value as an output.

[0090] As used herein, the term "patient sample" refers to a biological sample obtained from a patient, i.e., a recipient of medical attention, care, or treatment. The patient sample can be any of the samples described herein. In certain embodiments, the patient sample is obtained by a non-invasive procedure, e.g., a peripheral blood sample or a fecal sample. The methods described herein need not be limited to humans. Thus, various veterinary applications are contemplated where the patient sample can be a sample from a non-human mammal (e.g., cat, pig, horse, cow, etc.).

[0091] As used herein, the term "biological fluid" refers to a liquid taken from a biological source, including, for example, blood, serum, plasma, sputum, lavage fluid, cerebrospinal fluid, urine, semen, sweat, tears, saliva, and the like. As used herein, the terms "blood," "plasma," and "serum" expressly include fractions thereof or processed portions thereof. Similarly, if a sample is taken from a biopsy, swab, smear, etc., "sample" expressly includes processed fractions or portions obtained from the biopsy, swab, smear, etc.

[0092] As used herein, the term "corresponding" refers to a nucleic acid sequence, e.g., a gene or chromosome, that is present in the genomes of different subjects and does not necessarily have the same sequence in all genomes, but serves to provide the identity but not the genetic information of the sequence (e.g., gene or chromosome) of interest.

[0093] As used herein, the term "chromosome" refers to a genetic carrier of the present invention of a living cell, derived from a chromatin strand containing DNA and protein components (especially histones). The conventional internationally recognized individual human genome chromosome numbering system is used herein.

[0094] As used herein, the term "polynucleotide length" refers to the absolute number of nucleic acid monomer subunits (nucleotides) in a sequence or in a region of a reference genome. The term "chromosome length" refers to the known length of a chromosome given in base pairs, for example, as provided in the NCBI36 / hg18 assembly of human chromosomes found on the World Wide Web at |genome|.|ucsc|.|edu / cgi-bin / hgTracks?hgsid=167155613&chromInfoPage=.

[0095] As used herein, the term "subject" refers to non-human subjects such as mammals, invertebrates, vertebrates, fungi, yeast, bacteria, and viruses. Although the examples herein relate to humans and the language is primarily related to humans, the concepts disclosed herein are applicable to genomes from any plant or animal and are useful in veterinary medicine, animal science, laboratories, and such fields.

[0096] As used herein, the term "primer" refers to an isolated oligonucleotide that can act as an initiation point for synthesis when placed under conditions conducive to the synthesis of extension products (e.g., conditions include nucleotides, an inducing agent such as DNA polymerase, and suitable temperature and pH). The primer may be preferably single-stranded for maximum efficiency in amplification, or may be double-stranded. If double-stranded, it is first treated to separate its strands before being used to prepare extension products. The primer may be an oligodeoxyribonucleotide. The primer is sufficiently long to prime the synthesis of extension products in the presence of an inducing agent. The exact length of the primer depends on many factors, including temperature, source of primer, use of the method, and parameters used in primer design. introduction

[0097] Short tandem repeats (STRs) are ubiquitous throughout the human genome. Although our understanding of STR biology is incomplete, emerging evidence suggests that STRs play important roles in fundamental cellular processes.

[0098] Repeat expansion is a special class of microsatellite and minisatellite variants, including STR polymorphisms. Repeat expansion is also known as dynamic mutation due to the instability of short tandem repeats when they expand beyond a certain size. STR expansion is the main cause of more than 20 severe neurological diseases, including amyotrophic lateral sclerosis, Friedreich's ataxia (FRDA), Huntington's disease (HD), and fragile X syndrome. Table 1 illustrates a small number of pathogenic repeat expansions that differ from the repeat sequence in normal samples. The columns show the gene associated with the repeat sequence, the nucleic acid sequence of the repeat unit, the number of repeats of the repeat unit of normal and pathogenic sequences, and the disease associated with the repeat expansion. [Table 1]

[0099] Genetic diseases involving repeat expansions are heterogeneous in many respects. The size of the repeat unit, the degree of expansion, its location relative to the affected gene, and the pathogenic mechanism can vary from disease to disease. For example, ALS involves a hexanucleotide repeat expansion of the nucleotides GGGGCC in the C9orf72 gene located on the short arm of open reading frame 72 of chromosome 9. In contrast, fragile X syndrome is associated with an expansion of a trinucleotide repeat (triplet repeat) of CGG affecting the fragile X mental retardation 1 (FMR1) gene on the X chromosome. The expansion of the CGG repeats fails to express the fragile X mental retardation protein (FMRP), which is required for normal neurodevelopment. Depending on the length of the CGG repeat, the alleles can be classified as normal (not affected by the syndrome), premutation (risk for fragile X-associated disease), or full mutation (usually affected by the syndrome). According to various estimates, there are 230-4000 CGG repeats in the mutant FMR1 gene that causes fragile X syndrome in affected individuals, compared to 60-230 repeats in carriers with ataxia tendencies and 5-54 repeats in unaffected individuals. Repeat expansions in the FMR1 gene are the cause of autism, as approximately 5% of autistic patients are found to have FMR1 repeat expansions. McLennan, et al. (2011), Fragile X Syndrome, Current Genomics 12(3):216-224. Definitive diagnosis of fragile X syndrome involves genetic testing to determine the number of CGG repeats.

[0100] Several common characteristics of repeat expansion-associated diseases have been identified in multiple studies. Repeat expansion or dynamic mutation is usually expressed as an increase in the number of repeats, and the mutation rate is related to the number of repeats. Rare events such as the loss of a repeat interruption can result in an allele with increased probability of expansion, and such events are known as founder events. There may be a relationship between the number of repeats in a repeat sequence and the severity and / or onset of diseases caused by repeat expansion.

[0101] Therefore, identifying and calling repeat extensions is important in the diagnosis and treatment of various diseases. However, identifying repeat sequences, especially using reads that do not completely traverse the repeat sequence, has various challenges. First, it is difficult to align the repeat to the reference sequence because there is no clear one-to-one mapping between the read and the reference genome. In addition, even if the read is aligned to the reference sequence, the read is often too short to completely cover the medically relevant repeat sequence. For example, the read may be about 100 bp. In comparison, the repeat extension can span hundreds to thousands of base pairs. In fragile X syndrome, for example, the FMR1 gene can have well over 1000 repeats and span 3000 bp. Therefore, a 100 bp read cannot map the entire length of the repeat extension. Furthermore, assembling short reads into longer sequences may not overcome the problem of short reads vs. long repeats, because ambiguous alignment of the repeat in one read with the repeat on another read makes it difficult to assemble the short read into the longer sequence.

[0102] Alignment is the primary cause of information loss, either due to the completeness of the reference sequence, non-specific correspondence between reads and sites on the reference sequence, or significant deviation from the reference sequence. Systematic sequencing errors and other issues that affect read accuracy are secondary causes of failure to detect repeat sequences. In some experimental protocols, about 7% of reads are unaligned or have a MAPQ score of 0. Even if researchers work to improve sequencing techniques and analysis tools, there will always be a significant amount of unalignable and poorly aligned reads. The embodiments of the methods herein rely on unalignable or poorly aligned reads to identify repeat extensions.

[0103] Methods using long reads to detect repeat expansions have their own challenges. In next generation sequencing, currently available techniques that use longer reads tend to be slower and more error prone than techniques that use shorter reads. Furthermore, in some applications, such as sequencing cell-free DNA, long reads are not feasible. Cell-free DNA obtained from maternal blood can be used for prenatal genetic diagnosis. Cell-free DNA typically exists as fragments shorter than 200 using cell-free DNA. The embodiments of the methods described herein use short reads to identify medically relevant repeat expansions.

[0104] Furthermore, conventional methods are not designed to handle complex loci with multiple repeats. Important examples of such loci include the CAG repeat causing HD flanked by CCG repeats, the GAA repeat causing FRDA flanked by adenosine homopolymers, and the CAG repeat causing spinocerebellar degeneration type 8 (SCA8) flanked by CT repeats. An even more extreme example is the CCTG repeat in the CNBP gene, whose expansion causes myotonic dystrophy type 2 (DM2). This repeat is adjacent to polymorphic TG and TCTG repeats (JELee and Cooper 2009), making precise alignment of reads to this locus particularly challenging. Another type of complex repeat is the polyalanine repeat, which has been linked to at least nine diseases (Shoubridge and Gecz 2012). Polyalanine repeats consist of repeats of the α-amino acid codons GCA, GCC, GCG, or GCT.

[0105] Variant populations can affect alignment and genotyping accuracy (Lincoln et al. 2019). Variants adjacent to low-complexity polymorphic sequences can be even more problematic as methods for variant discovery may output clusters of consistently represented or false variant calls in such genomic regions. This is due, in part, to elevated error rates in such regions in sequencing data (Benjamini and Speed ​​2012; Dolzhenko et al. 2017). One example is the single nucleotide variant (SNV) adjacent to an adenosine homopolymer in MSH2 that causes Lynch syndrome I (Froggatt et al. 1999).

[0106] The embodiments disclosed herein are capable of handling such complex loci. They use a sequence graph as a general and flexible model for each target locus.

[0107] In some embodiments, the disclosed methods address the aforementioned challenges in identifying and calling repeat extensions by utilizing paired-end sequencing. Paired-end sequencing involves fragmenting DNA into sequences, called inserts. In some protocols used by Illumina, reads from shorter inserts (e.g., about 10 to several hundred bp) are referred to as short-insert paired-end reads, or simply paired-end reads. In contrast, reads from longer inserts (e.g., about several thousand bp) are referred to as mate pair reads. As discussed above, both short-insert paired-end reads and long-insert mate pair reads may be used in various embodiments of the methods disclosed herein.

[0108] FIG. 1A is a schematic diagram illustrating certain difficulties in aligning sequence reads to repetitive sequences on a reference sequence, especially when aligning sequence reads obtained from a sample of long repetitive sequences with repeat expansions. At the bottom of FIG. 1A, there is a reference sequence 101 with a relatively short repetitive sequence 103, indicated by vertical hatch lines. In the middle of the figure, there is a hypothetical sequence 105 of a patient sample with a long repetitive sequence 107, also indicated by vertical hatch lines. At the top of the figure, there are sequence reads 109 and 111 shown at the location of the corresponding site in the sample sequence 105. In some of these sequence reads, such as read 111, some base pairs arise from the long repetitive sequence 107, highlighted with a circle, also indicated by vertical hatch lines. Reads 111 with these repeats are potentially difficult to align to the reference sequence 101 because the repeats do not have a clear corresponding position on the reference sequence 101. It is difficult to obtain information about the repetitive sequences and the extension of the repetitive sequences from these potential unaligned reads 111 because they cannot be clearly associated with the repetitive sequences 103 in the reference sequence 101. Furthermore, these reads tend to be shorter than the long repetitive sequences 107 with repeat extensions, and therefore cannot directly provide clear information about the identity or location of the repetitive sequences 107. In addition, the repeats in the reads 111 are difficult to assemble due to their ambiguous corresponding locations on the reference sequence 101 and the ambiguous relationship between the reads 111. Reads that arise partially from the long repetitive sequences 107 in the sample, shown as semi-hatched and semi-solid black, may be aligned by bases that arise outside the repetitive sequences 107. If the reads have too few base pairs outside the repetitive sequences 107, the reads may be poorly aligned or may not be aligned. Therefore, some of these reads with partial repeats may be analyzed as anchored reads, and others may be analyzed as anchored reads, as described further below.

[0109] FIG. 1B is a schematic diagram showing how paired-end reads can be utilized in some disclosed embodiments to overcome the difficulties shown in FIG. 1A. In paired-end sequencing, sequencing occurs from both ends of a nucleic acid fragment in a test sample. Shown at the bottom of FIG. 1B are a reference sequence 101 and a sample sequence 105, as well as reads 109 and 111 equivalent to those shown in FIG. 1A. Shown at the top of FIG. 1B are a fragment 125 derived from the test sample sequence 105, as well as a primer region 131 of read 1 and a primer region 133 of read 2 to obtain two reads 135 and 137 of a paired-end read. The fragment 125 is also referred to as an insert for a paired-end read. In some embodiments, the insert may be amplified with or without PCR. Some repetitive sequences, such as those containing a large number of GC or GCC repeats, cannot be well sequenced by traditional methods involving PCR amplification. For such sequences, the amplification may not involve PCR. For other sequences, amplification may be carried out by PCR.

[0110] The insert 125 shown in FIG. 1B corresponds to or is derived from a section of the sample sequence 105 flanking the two vertical arrows shown in the bottom half of the figure. Specifically, the insert 125 has a repeat section 127 that corresponds to a portion of the long repeat 107 in the sample sequence 105. The length of the insert may be adjusted for various applications. In some embodiments, the insert may be somewhat shorter than the repeat sequence or repeat sequence with repeat extension of interest. In other embodiments, the insert may have a similar length to the repeat sequence or repeat sequence with repeat extension. In still further embodiments, the insert may be somewhat longer than the repeat sequence or repeat sequence with repeat extension. Such an insert may be a long insert for mate pair sequencing in some embodiments described further below. Typically, the reads obtained from the insert are shorter than the repeat sequence. Because the insert is longer than the read, paired end reads can better capture signal from longer stretches of repeat sequences in a sample than single end reads.

[0111] The illustrated insert 125 has two read primer regions 131 and 133 on two edges of the insert. In some embodiments, the read primer regions are native to the insert. In other embodiments, the primer regions are introduced into the insert by ligation or extension. At the left end of the insert, a read 1 primer region 131 is shown, which allows hybridization of read 1 primer 132 to the insert 125. Extension of read 1 primer 132 generates a first read or read 1, labeled as 135. At the right end of the insert 125, a read 2 primer region 133 is shown, which allows hybridization of read 2 primer 134 to the insert 125, which initiates a second read or read 2, labeled as 137. In some embodiments, the insert 125 may also include an index barcode region (not shown here) which may provide a mechanism for identifying different samples in a multiplex sequencing process. In some embodiments, paired-end reads 135 and 137 can be obtained by an Illumina sequencing by synthesis platform, an example of a sequencing process performed on such a platform is further described below in the Sequencing Methods section, which produces two paired-end reads and two index reads.

[0112] The resulting paired-end reads may then be aligned to a reference sequence 101 having a relatively short repetitive sequence 103, as shown in FIG. 1B. In this way, the relative position and orientation of the pair of reads is known. This allows unalignable or poorly aligned reads, such as those shown in circle 111, to be indirectly associated with a relatively long repetitive sequence 107 in the sample sequence 105 through their corresponding paired reads 109, as seen at the bottom of FIG. 1B. In an exemplary embodiment, the reads obtained from paired-end sequencing are about 100 bp and the inserts are about 500 bp. In this exemplary setup, the relative positions of the two paired-end reads are about 300 base pairs from their 3' ends, and they have opposite orientations. The relationship between the read pairs allows one read to be better associated with the repetitive region. In some cases, the first read of the pair aligns with a non-repetitive sequence flanking the repetitive region on the reference sequence, and the second read of the pair does not align properly to the reference sequence. For example, referring to the pair of reads 109a and 111a shown in the bottom half of FIG. 1B, the left one 109a of the pair is the first read and the right one 111a is the second read. Considering the pair of two reads 109a and 111a, the second read 111a can be associated with the repeat region 107 in the sample sequence 105, despite the fact that the second read 111a cannot be aligned to the reference sequence 101. By knowing the distance and orientation of the second read 111a relative to the first read 109a, the position of the second read 111a in the long repeat region 107 can be further determined. If there is a break between the repeats in the second read 111a, the position of the break relative to the reference sequence 101 can also be determined. A read such as the left read 109a aligned to the reference is referred to as an anchor read in the present disclosure. A read such as the right one 111a that is not aligned to the reference sequence but is paired with an anchor read is referred to as an anchored read. Thus, non-aligned sequences can be anchored and associated with the repeat expansion. In this way, short reads can be used to detect long repeat expansions.Although the challenge of detecting repeat extensions typically increases with the length of the extension due to sequencing difficulties, the methods disclosed herein are able to detect higher signals from longer repeat extension sequences than from shorter repeat extension sequences, because as the repeat sequence or repeat extension becomes longer, more reads are anchored in the extension region, more reads fall completely within the repeat region, and more repeats can occur per read.

[0113] In some embodiments, the disclosed method includes analyzing the frequency distribution of the number of repeats found in the anchored reads and the anchored reads. In some embodiments, only the anchored reads are analyzed. In other embodiments, both the anchored reads and the anchored reads are analyzed. The distribution of the test sample can be compared to an empirical or theoretically derived criterion that separates unaffected samples from affected samples. In this way, it can be determined whether the test sample has the repeat expansion under consideration and a clinically relevant call can be made.

[0114] The methods and devices described herein can employ next-generation sequencing technology (NGS), thereby enabling massively parallel sequencing. In certain embodiments, clonally amplified DNA templates or single DNA molecules are sequenced in a massively parallel manner in a flow cell (e.g., as described in Volkerding et al. Clin Chem 55:641-658

[2009] ; Metzker M Nature Rev 11:31-46

[2010] ). Sequencing techniques for NGS include, but are not limited to, pyrosequencing, sequencing-by-synthesis with reversible dye terminators, sequencing by oligonucleotide probe ligation, and ion semiconductor sequencing. DNA from each sample can be sequenced individually (i.e., singleplex sequencing), or DNA from multiple samples can be pooled as indexed genomic molecules on a single sequencing run (i.e., multiplex sequencing) to generate up to millions of DNA sequences. Examples of sequencing technologies that can be used to obtain sequence information by the present methods are described further below.

[0115] Various repeat extension analyses using DNA samples involve aligning or mapping sequence reads from a sequencer to a reference sequence. The reference sequence may be the sequence of the whole genome, the sequence of a chromosome, the sequence of a partial chromosomal region, etc. From a computational perspective, repeats can cause alignment ambiguity, which in turn can cause bias and error even at the overall chromosome counting level. In various embodiments, paired-end reads combined with adjustable insert length can eliminate ambiguity in the alignment of repeat sequences and aid in the detection of repeat extensions. Genotyping variants at repetitive sequence loci using sequence graphs

[0116] Figure 1C shows a flow chart illustrating a process 140 for genotyping genomic loci that contain repetitive sequences, according to some embodiments. In some embodiments, the loci are predefined in a variant catalog that contains the genomic location and the structure of the locus at the genomic location. Figures 1D, 1E, and 1F show three different sequence graphs, according to some embodiments.

[0117] Figure 1G shows a schematic of a process for genotyping variants in HTT that include two STR sequences, according to some embodiments. Figure 1G panel (a) shows a portion of a variant catalog that includes genomic loci and their structures as locus specifications. For example, ignoring repeats, the sequence at locus HTT is CAGCAACAGCGG (SEQ ID NO: 2) and the sequence at locus CNBP is CAGGCAGACA (SEQ ID NO: 3).

[0118] Figure IH shows a schematic of a process for genotyping variants at the Lynch I locus, including SNVs and STRs, according to some embodiments. Box 162 in Figure IH shows the general structure of a locus specification, and box 163 shows an example of a locus specification for Lynch I (MSH2).

[0119] In the allotype catalog, locus structure is specified using a restricted subset of regular expression syntax. For example, the expression (CAG) shows that the repetitive region bound to HD has a variable number of CAG and CCG repeats separated by CAACAG interruptions. * CAACAG(CGG) * or SEQ ID NO:2 (ignoring repeats). The region bound to the FRDA region is expressed (A) * (GAA) * The region bound to SCA8 corresponds to (CTA) * (CTG) * The DM2 repeat region, consisting of three adjacent repeats, corresponds to (CAGG) * (CAGA) * (CA)* or the MSH2 SNV defined by SEQ ID NO:3 (repeat neglect) and adjacent to the homopolymer causing Lynch syndrome I is (A|T)(A) * Corresponds to.

[0120] Additionally, normal expression allows for the inclusion of multiple alleles, or "degenerate" base abbreviations, which can be specified using the International Union of Pure and Applied Chemistry (IUPAC) notation ("Nomenclature for Incompletely Specified Bases in Nucleic Acid Sequences. Recommendations 1984. Nomenclature Committee of the International Union of Biochemistry (NC-IUB)" 1986).

[0121] An incompletely specified base corresponding to a base in a degenerate codon is referred to herein as a degenerate base. By degenerating bases, certain classes of incomplete DNA repeats can be represented, for example, where different bases can occur at the same position. This notation is used to refer to the expression (GCN) * Polyalanine repeats can be encoded by the CAR-expressing (CAR) * It can be coded as follows:

[0122] In some embodiments, the repeat sequence contained in the genomic locus comprises a short tandem repeat (STR) sequence. In some embodiments, the expansion of the FTR is associated with fragile X syndrome, amyotrophic lateral sclerosis (ALS), Huntington's disease, Friedreich's ataxia, spinocerebellar degeneration, spinal-bulbar muscular atrophy, myotonic dystrophy, Machado-Joseph disease, or dentatorubral-pallidoluysian atrophy.

[0123] Process 140 includes collecting nucleic acid sequence reads for a test sample from a database. See block 142. In some embodiments, the nucleic acid sequence reads are first aligned to a reference genome, but the process herein realigns the sequence reads to genomic loci of interest, as described below. In alternative embodiments, the reads may be aligned directly to a sequence graph without first being aligned to a reference genome.

[0124] Process 140 includes aligning sequence reads to sequences for genomic loci that include one or more repeat sequences. See block 144. Sequences of genomic loci are represented by data stored in a system memory having a sequence graph data structure. The sequence graph includes a directed graph having vertices that represent nucleic acid sequences and directed edges connecting the vertices. The nucleic acid sequences in the vertices include one or more nucleic acid bases. The sequence graph includes one or more self-loops. Each self-loop represents a repeat sequence of one or more repeat sequences. Each repeat sequence includes repeats of one or more nucleotide repeat units.

[0125] In some embodiments, sequence reads are first aligned to a reference genome to determine the genomic coordinates of the reads before a subset of the initially aligned reads are aligned to one or more sequence graphs representing one or more sequences of interest. In some embodiments, the initially aligned reads determine repeat expansions in tens to thousands of regions, each region corresponding to a sequence graph. The total number of initially aligned reads that are realigned to a sequence graph during each implementation of an embodiment can range from thousands to millions of reads.

[0126] In some embodiments, reads that are first aligned to or near a sequence or locus of interest are selected as a subset of reads, and the subset is then aligned to repeat sequences each represented by a sequence graph, the sequence graph having one or more self-loops representing one or more repeated sequences. In various embodiments, reads within about 10, 50, 100, 500, 1,000, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 50,000, 100,000 bases from a sequence or locus of interest are considered to be near the sequence or locus of interest. In some embodiments, reads within about 1,000, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, or 10,000 bases from the locus of interest are near the locus of interest. Some of the raw reads may be initially poorly aligned, for example, because they contain repetitive sequences that are difficult to align unambiguously. In some embodiments, reads that are initially poorly aligned (e.g., as measured by alignment score) are paired with reads that are aligned to or near the locus of interest (paired-end read pairs), respectively. In some embodiments, reads that are initially aligned to off-target regions that are known hotspots for misaligning reads are aligned to the sequence graph.

[0127] 1D, 1E, and 1F show three different sequence graphs according to some embodiments. FIG. 1D shows a first sequence graph 1100 representing a first genomic locus that includes a repeat sequence with the trinucleotide repeat unit CAG. The first sequence graph 1100 includes vertices 1102 and 1112, each of which represents two adjacent sequences. The first sequence graph also includes vertex 1106, which represents a repeat sequence that includes the trinucleotide repeat unit CAG. The first sequence graph includes a directed edge 1104 connecting vertex 1102 (the adjacent sequence) and vertex 1106 (the CAG repeat sequence), with the direction going from vertex 1102 to vertex 1106. The direction of the edge indicates the relative position of the two nucleic acid sequences. The first sequence graph also includes a directed edge 1104 connecting vertex 1102 (the adjacent sequence) and vertex 1106 (the CAG repeat sequence), with the direction going from vertex 1102 to vertex 1106. The first sequence graph also includes a directed edge 1110 connecting vertex 1106 (the CAG repeat sequence) and vertex 1112 (the flanking sequence), with the direction going from vertex 1106 to vertex 1112. The first sequence graph also includes a self-loop 1108, which represents that the repeat sequence includes the repeat unit CAG (shown at vertex 1106) that repeats one or more times. The path going from the start vertex to the end vertex of the sequence graph represents the sequence of a genomic locus, which may include nucleotides near the repeat sequence, such as the flanking sequence.

[0128] FIG. 1E shows a second sequence graph 1200 representing a second genomic locus. The second sequence graph 1200 includes vertices 1202 and 1224, each of which represents two adjacent sequences. The second sequence graph also includes vertices 1206 and 1216, which represent a repetitive sequence that includes the trinucleotide repeat unit CAG and a repetitive sequence that includes the trinucleotide repeat unit CCG, respectively. The second sequence graph further includes vertex 1212, which represents a non-repetitive sequence CAACAG. The second sequence graph includes directed edges 1204, 1210, 1214, and 1220. These directed edges connect vertices 1202, 1206, 1212, 1216, and 1224 in a directed manner as shown. The second sequence graph also includes a self-loop 1208, which represents that the repetitive sequence includes the repeat unit CAG (shown at vertex 1206) that repeats one or more times. The second sequence graph also includes a self-loop 1218, which represents that the repeating sequence includes a repeating unit CCG (shown at vertex 1216) that repeats one or more times.

[0129] FIG. 1F shows a third sequence graph 1300 representing a third genomic locus. The third sequence graph 1300 is similar to the second sequence graph 1200, but includes two alternative paths representing two alleles, CAC and CAT. The two alleles may be SNV or SNP alleles. Directed edge 1310, vertex 1312, and directed edge 1314 represent a first allele of CAC. Directed edge 1316, vertex 1318, and directed edge 1320 represent a second allele of CAT. The third sequence graph includes elements similar to those in the second sequence graph, including vertices 1302, 1306, 1322, and 1328. It also includes self-loops 1308 and 1324 representing the repeated sequences CAG repeat and CCG repeat. It further includes directed edges 1304 and 1326.

[0130] In some embodiments, sequence reads are aligned to a sequence graph using the techniques described below.

[0131] 1. The Kmer index is constructed over the entire graph such that, given a kmer from an array, it is possible to enumerate all graph nodes where such a kmer begins or ends. In some cases, a kmer may begin on one node and end on another.

[0132] 2. For each graph hit, extract two subgraphs, one in the forward direction of the kmer and one in the reverse direction. The subgraphs expand the repeat extensions up to the remaining read length, but do not contain any nodes that are further away from the kmer hit than the remaining read length, assuming the repeats have not been extended. The procedure is a breadth-first search, producing a data structure that contains:

[0133] -Concatenation of all node sequences (including expanded repeats) in the subgraph

[0134] -The index of a node, so that the node ID can be easily obtained from its offset in the array when backtracking in the Smith-Waterman algorithm.

[0135] - an array of offsets for the end nodes that the edge is in, relative to the start offset of each node

[0136] - An index for each node, making it easy to indicate whether a base is at the start of a node or not at the start of a node, and also to list all the terminal offsets of the previous nodes.

[0137] 3. Alignment

[0138] -Supports affine gaps.

[0139] - Find the best scoring alignment(s) for the sequences given the above information and the penalty matrix.

[0140] Two diff interfaces are available:

[0141] -The best alignment and the second best alignment scores are reported.

[0142] - The entire array of best alignment and second best alignment scores.

[0143] The alignment is a global alignment that penalizes for gaps between the candidate kmer and the start of the aligned sequence.Some embodiments fine-tune two compile-time parameters.

[0144] The current algorithm for matrix filling is available in two embodiments.

[0145] -N * A continuous loop with complexity M.

[0146] - Fixed length compile time parameters, with a default selection of 16 for consecutive loops of fixed size loops, so gcc will automatically recognize and translate SSE or AVX vector instructions on your CPU.

[0147] In some embodiments, a particular repeat unit of a repeat sequence of one or more repeat sequences comprises at least one incompletely specified nucleotide, hi some embodiments, a particular repeat unit comprises a degenerate codon.

[0148] In some embodiments, the one or more self-loops include two or more self-loops representing two or more repeat sequences, see, e.g., panels (b) of Figures 1E, 1F, and 1G.

[0149] In some embodiments, the sequence graph further comprises two or more alternative pathways for two or more alleles. See, e.g., Figure IF, reference numbers 1312 and 1318. See also Figure 1H, reference numbers 165 and 167a for locus Lynch I (MSH2), the upper pathway includes a vertex at nucleobase A and the lower pathway includes a vertex at nucleobase T.

[0150] In some embodiments, two or more alleles comprise an indel or a substitution. In some embodiments, the substitution comprises a single nucleotide variant (SNV) or a single nucleotide polymorphism (SNP). See, e.g., FIG. 1F, reference numbers 1312 and 1318.

[0151] In some embodiments, aligning the sequence reads to the sequence graph includes finding a kmer match between the sequence reads and a path in the sequence graph and then extending the path into a full alignment. In some embodiments, the alignment includes extracting a subgraph around the path, unrolling any loops in the subgraph to obtain a directed acyclic graph, and performing a Smith-Waterman alignment of the sequence reads against the directed acyclic graph.

[0152] In some embodiments, aligning sequence reads to a sequence graph involves reducing the graph by eliminating results with low confidence in the alignment. After the reads are aligned to the graph, the method searches for other similar alternative alignments. This is done by realigning the original reads to a path through the graph that overlaps with the path of the original alignment. This allows for example to detect cases where one or both ends of the initial alignment have low confidence, indicating that they may have been aligned in a different way. Being able to detect high and low confidence parts of the alignment allows for accurate determination of which genetic variants the reads support.

[0153] In some embodiments, aligning the sequence reads to the sequence graph comprises aligning subsequences of the reads to the sequence graph and merging the sequences of the subsequences to form a complete sequence of the sequence read.

[0154] In some embodiments, the process also includes generating a sequence graph based on a locus specification that includes a locus structure of the genomic locus, in some embodiments, the locus specification is defined in a variant catalog as described above.

[0155] See also Figure 1G, panels (b)-(d) for a schematic of read alignment to a sequence graph of the HTT locus. Figure 1H shows a schematic of a locus analyzer 164 for performing alignment of reads to a sequence graph, such as the locus Lynch I (165).

[0156] Process 140 further includes determining one or more genotypes of one or more repeat sequences using sequence reads aligned to the sequence graph. See block 140. See also panel (e) of FIG. 1G, which shows determining two STRs (CAG and CCG) at the HTT locus. The left sequence containing the CAG repeat is CAGCAGCAGCAGCAG (SEQ ID NO: 4). The left sequence containing the CCG repeat is CCGCCGCCGCCGCCCG (SEQ ID NO: 5).

[0157] FIG. 1H shows a variant genotyper module (168) for determining variants at the Lynch I locus, including an SNV with an A / T allele (169a) and an A monomer repeat (169b). FIG. 1H also shows a variant analyzer module (166) for curating sequence alignment data and providing them to the variant genotyper (168), and an example variant analyzer for an SNV with an A / T allele (167a) and an A monomer repeat (167b). The locus results from the genotype are shown in box 170 of FIG. 1H, specifically as the genotype of the SNV with an A / T allele (171a) and an A monomer repeat (171b).

[0158] In some embodiments, the sequence graph includes two alternative pathways for the two alleles, and the method further includes genotyping the two or more alleles using sequence reads aligned to the two or more alternative pathways. In some embodiments, genotyping the two or more alleles includes providing coverage of the two or more alternative pathways to a probabilistic model to determine probabilities of the two or more alleles. In some embodiments, the probabilistic model simulates the probabilities of the alleles as a function of coverage of the alleles, where the function is selected from a Poisson distribution, a negative binomial distribution, a binomial distribution, or a beta-binomial distribution.

[0159] In some embodiments, the probability function is a Poisson distribution, whose kinetic parameters are estimated from the read length and average depth observed at the genomic locus.

[0160] In the Poisson model, the allele probabilities are expressed as follows:

[0161] P(Y=y)=(C y ×e -C ) / y!

[0162] y is the read probability of the base.

[0163] C is the average depth at the genomic locus.

[0164] In some embodiments, the average depth C is

[0165] It is estimated as C=LN / G.

[0166] G is the length of the genomic locus.

[0167] L is the lead length.

[0168] N is the number of all reads. Graph Tools Library

[0169] In some embodiments, basic sequence graph functionality is applied using the GraphTools library, which implements the core graph extractions (the graph itself, graph paths, and graph alignments), their operations, and algorithms for aligning linear sequences into graphs.

[0170] In some embodiments, the sequence graph consists of nodes and directed edges. The graph can contain self-loops (edges connecting a node to itself) but no other cycles. The nodes contain sequences consisting of core bases and IUPAC degenerate base codes.

[0171] A graph path is defined by the sequence of nodes that the path passes through along with the path's start location on the first node and the end location on the last node. Locations are specified using a zero-based semi-open coordinate system. The library defines several operations on paths including path extension and contraction, overlap checking, and path merging.

[0172] Graph alignment encodes how a linear query sequence (usually a sequenced read) is aligned to a graph. In some embodiments, a graph alignment includes a graph path and an array of linear alignments that define the alignment of the query sequence to the nodes of the graph path. Graph alignments can be contracted or merged with other graph alignments using corresponding operations on the paths. Path contraction provides a mechanism for removing unreliable alignment ends, while alignment merging is used by the graph alignment algorithm to stitch together a complete alignment of the query sequence from the alignment of subsequences (e.g., kmers). In some embodiments, the alignment algorithm operates by finding a kmer match between the query sequence and the graph, and then stretching this match into a complete alignment. In some embodiments, the alignment includes extracting a subgraph around the path that corresponds to the kmer match (unrolling any loops in the process). It then performs a Smith-Waterman alignment on the resulting directed acyclic graph. In some embodiments, the algorithm is written using constant-length loops to support affine gap penalties and to allow compilation to generate SIMD code.

[0173] In some embodiments, a graph path can be obtained using a search algorithm that involves extending or shrinking the path by increasing or decreasing the number of iterations of repeating units represented by self-loops until the alignment reaches a search criterion or convergence (e.g., the alignment score is maximized).

[0174] In some embodiments, a plurality of graph paths are generated from the sequence graph, each graph path representing a particular number of iterations of a repeating unit represented by a self-loop. The query sequence is aligned to the plurality of graph paths, and then paths that satisfy the alignment criteria are selected for graph alignment. Application Architecture

[0175] Some embodiments are designed as a general tool for targeted variant genotyping (Figure 1H). During each run, the program attempts to genotype a set of variants.

[0176] The locus structure is specified using a restricted subset of the Regular Expression (RE) syntax. Res contains a sequence over an alphabet consisting of core base abbreviations and IUPAC degenerate base codes, and optionally one or more expressions (<sequence>)?, (<sequence a>|<sequence b>), (<sequence>) separated by sequence breaks. * , (<sequence>)+. These representations correspond to insertions / deletions, substitutions, sequences repeated 0 or more times, and sequences repeated at least once each. Additionally, each locus description includes a set of reference regions for the locus and reference coordinates for each constituent variant.

[0177] The bulk of the work is orchestrated in a coordinated manner by an object of the Locus Analyzer class, which during initialization synthesizes a sequence graph representing the loci from the corresponding RE. After initialization, the Locus Analyzer processes the associated reads by aligning them into a graph and then passing the resulting alignment to a Variant Analyze defined for each variant contained in the locus. The Variant Analyzer extracts the relevant information to genotype the associated variants and passes it to a Genotyper that performs the actual genotyping. The results output by each Genotyper are then used to create an output VCF file.

[0178] For example, the locus analyzer involved in processing loci with pathogenic variants associated with Lynch I syndrome utilizes an SNV analyzer and a STR analyzer (Figure S1, right panel). Indel genotyper

[0179] Some STRs may have small insertions or deletions (indels) nearby. Such indels are modeled as additional subgraphs in the adjacent sequences of the STR. The number of reads mapped to each allele (or graph path) is modeled with a Poisson distribution, whose rate parameters are estimated from the average depth and read length observed at the locus. Genotype likelihoods are calculated under a Bayesian framework. Identification of repeat expansions

[0180] Using the embodiments disclosed herein, various genetic conditions associated with repeat expansions can be determined with high efficiency, sensitivity, and / or selectivity compared to conventional methods. Some embodiments of the present invention provide methods for identifying and calling medically relevant repeat expansions, such as the CGG repeat expansions that cause mental retardation in Fragile X syndrome, using sequence reads that do not completely traverse the repeat sequences. Short reads, such as 100 bp reads, are not long enough to sequence through many repeat expansions. However, when analyzed with the disclosed methods, samples with repeat expansions show a statistically significant excess of reads that contain many repeat sequences. In addition, very large repeat expansions include unaligned read pairs, where both reads are completely or nearly completely composed of repeat sequences. A standard sample is used to identify background expectations.

[0181] The conventional belief is that repeat extensions cannot be detected without reads that span the entire repeat. Previous approaches to detect repeat extensions use targeted sequencing with long reads where the reads were non-normal because they were not long enough to span the repeat sequence. The results of some disclosed embodiments have been surprisingly satisfactory for using normal (non-targeted) sequence data and using read lengths of only about 100 bp, but resulting in very high sensitivity for detecting repeat extensions. The methods described herein can detect the number of repeat units in a repeat extension using paired reads with an insert length (i.e., two sequence reads and an intervening sequence) that is shorter than the length of the entire repeat sequence.

[0182] Turning now to the details of a method for determining the presence of a repeat expansion according to some embodiments, FIG. 2 shows a flow diagram providing a high level depiction of an embodiment for determining the presence or absence of a repeat expansion of a repetitive sequence in a sample. A repeat sequence is a nucleic acid sequence that contains a repetitive appearance of short sequences called repeat units. Table 1 above provides examples of repeat units, the number of repeats of the repeat units in the repeat sequences of normal and pathogenic sequences, genes associated with the repeat sequences, and examples of diseases associated with repeat expansion. Process 200 of FIG. 2 begins by obtaining paired-end reads of a test sample. See block 202. The paired-end reads are processed to be aligned to a reference sequence that contains the repeat sequence of interest. In some syntaxes, the alignment process is also referred to as a mapping process. The test sample includes nucleic acid and may be in the form of a body fluid, tissue, etc., as further described in the Sample section below. The sequence reads are subjected to an alignment process to map to a reference sequence. As described elsewhere in this disclosure, various alignment tools and algorithms may be used to attempt to align the reads to the reference sequence. Typically, in an alignment algorithm, some reads are normally aligned to the reference sequence, while other reads may not be normally aligned to the reference sequence or may not be aligned to the reference sequence. Reads aligned consecutively to the reference sequence are associated with sites on the reference sequence. The aligned reads and their associated sites are also called sequence tags. As mentioned above, some sequence reads that contain a large number of repeats tend to be more difficult to align to the reference sequence. A read is considered to be poorly aligned if it is aligned to a reference sequence with more mismatched bases than a certain criterion. In various embodiments, a read is considered to be poorly aligned if it is aligned with at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mismatches. In other embodiments, a read is considered to be poorly aligned if it is aligned with at least about 5% mismatches. In other embodiments, a read is considered to be poorly aligned if it is aligned with at least about 10%, 15%, or 20% mismatched bases.

[0183] As shown in FIG. 2, process 200 proceeds to identify anchor reads and anchored reads within the paired-end reads. See block 204. An anchor read is a read between paired-end reads that is aligned to or near a repeat sequence of interest. For example, an anchor read can be aligned to a position on a reference sequence that is separated from the repeat sequence by a sequence length that is shorter than the sequence length of the insert. The separation length may be shorter. For example, an anchor read can be aligned to a position on a reference sequence that is separated from the repeat sequence by a sequence length that is shorter than the sequence length of the anchor read, or a sequence length that is less than the combined sequence length of the anchor read and the sequence that connects the anchor read to the anchored read (i.e., the length of the insert minus the length of the anchored read). In some embodiments, the repeat sequence may be a repeat sequence in the FMR1 gene that includes repeats of the repeat unit CGG. In a typical reference sequence, the repeat sequence in the FMR1 gene includes about 6 to 32 repeats of the repeat unit CGG. When the repeat is expanded beyond 200 copies, the repeat expansion tends to become pathogenic and cause fragile X syndrome. In some embodiments, a read is considered to be aligned near a target sequence if it is aligned within 1000bp of the target repeat sequence. In other embodiments, this parameter may be adjusted, such as within about 100bp, 200bp, 300bp, 400bp, 500bp, 600bp, 700bp, 800bp, 900bp, 1500bp, 2000bp, 3000bp, 5000bp, etc. In addition, it also identifies anchored reads that are paired with anchored reads but are poorly aligned or cannot be aligned with their reference sequence. Further details of poorly aligned reads are described above.

[0184] Process 200 further includes determining whether a repeat expansion of a repetitive sequence is likely to be present in the test sample based at least in part on the identified anchored reads. See block 206. This determining step can include various suitable analyses and calculations, as described further below. In some embodiments, the process uses the identified anchored reads, as well as the anchored reads, to determine whether a repeat expansion is likely to be present. In some embodiments, the number of repeats in the identified anchors and anchored reads is analyzed and compared to one or more criteria derived theoretically or derived from empirical data of influenced control samples.

[0185] In various embodiments described herein, the repeats are obtained as in-frame repeats, where two repeats of the same repeat unit fall into the same reading frame. A reading frame is a method of dividing a nucleotide sequence in a nucleic acid (DNA or RNA) molecule into a set of consecutive non-overlapping triplets. During translation, the triplets code for amino acids and are called codons. Thus, any particular sequence has three possible reading frames. In some embodiments, the repeats are counted according to three different reading frames, and the maximum of the three counts is determined to be the number of corresponding repeats that are read.

[0186] An example of a process with additional operations and analyses is shown in FIG. 3. FIG. 3 shows a flow diagram illustrating a process 300 for detecting repeat extensions using paired-end reads with a large number of repeats. The process 300 includes additional upstream processing of the test sample. The process begins by sequencing a test sample containing nucleic acid to obtain paired-end reads. See block 302. In some embodiments, the test sample may be obtained and prepared in a variety of ways, as further described in the Sample section below. For example, the test sample may be a biological fluid, e.g., plasma, or any suitable sample described below. The sample may be obtained using a non-invasive procedure, such as a simple blood draw. In some embodiments, the test sample contains a mixture of nucleic acid molecules, e.g., cfDNA molecules. In some embodiments, the test sample is a maternal plasma sample containing a mixture of fetal and maternal cfDNA molecules.

[0187] Prior to sequencing, nucleic acids are extracted from the sample. Suitable extraction processes and devices are described elsewhere herein. In some embodiments, the device processes DNA from a total of multiple samples to provide multiplexed libraries and sequence data. In some embodiments, the device 20 processes DNA from eight or more test samples in parallel. As described below, the sequencing system can process the extracted DNA to generate a library of coded (e.g., barcoded) DNA fragments.

[0188] In some embodiments, the nucleic acids in the test sample may be further processed to prepare a sequencing library for multiplex or singleplex sequencing, as further described in the Sequencing Library Preparation section below. After the sample has been processed and prepared, sequencing of the nucleic acids may be performed by a variety of methods. In some embodiments, a variety of next generation sequencing platforms and protocols may be employed, as further described in the Sequencing Methods section below.

[0189] Regardless of the particular sequencing platform and protocol, at least a portion of the nucleic acids contained in the sample are sequenced in block 302 to generate hundreds of thousands, millions, or millions of sequence reads (e.g., 100 bp reads). In some embodiments, the reads include paired-end reads. In other embodiments, such as those described below with respect to FIG. 5, in addition to paired-end reads, single-end long reads containing hundreds, thousands, or hundreds of thousands of bases may be used to determine repeat sequences. In some embodiments, the sequence reads comprise about 20bp, about 25bp, about 30bp, about 35bp, about 36bp, about 40bp, about 45bp, about 50bp, about 55bp, about 60bp, about 65bp, about 70bp, about 75bp, about 80bp, about 85bp, about 90bp, about 95bp, about 100bp, about 110bp, about 120bp, about 130, about 140bp, about 150bp, about 200bp, about 250bp, about 300bp, about 350bp, about 400bp, about 450bp, or about 500bp. It is anticipated that technological advances will enable single-end reads of greater than 500bp, and, when paired-end reads are generated, reads of greater than about 1000bp.

[0190] Process 300 proceeds to align the paired-end reads obtained from block 302 to a reference sequence that includes the repetitive sequences. See block 304. In some embodiments, the repetitive sequences are subject to expansion. In some embodiments, repeat expansions are known to be associated with genetic disease. In other embodiments, repeat expansions of repetitive sequences have not previously been studied to establish an association with genetic disease. The methods disclosed herein allow for the detection of repetitive sequences and repeat expansions regardless of any associated pathology. In some embodiments, the reads are aligned to a reference genome, such as hg18. In other embodiments, the reads are aligned to a portion of a reference genome, such as a chromosome or chromosome segment. Reads that uniquely map to a reference genome are known as sequence tags. In one embodiment, at least about 3×10 6 Limited sequence tags, at least about 5 × 10 6 Limited sequence tags, at least about 8 × 10 6 Limited sequence tags, at least about 10 × 10 6 Limited sequence tags, at least about 15 × 10 6 Limited sequence tags, at least about 20 × 10 6 Limited sequence tags, at least about 30 × 10 6 Limited sequence tags, at least about 40 × 10 6 or at least about 50×10 6 Limited sequence tags are obtained from reads that uniquely map to the reference genome.

[0191] In some embodiments, the process can filter sequence reads before alignment. In some embodiments, the filtering of reads is a quality filtering process that is enabled by a software program implemented in the sequencer to filter erroneous and low-quality reads. For example, Illumina's Sequencing Control Software (SCS) and Consensus Assessment of Sequence and Variation software programs filter erroneous and low-quality reads by converting raw image data generated by sequencing reactions into intensity scores, base calls, quality score alignments, and additional formats to provide biologically relevant information for downstream analysis.

[0192] In certain embodiments, the reads generated by the sequencing device are provided in electronic format. Alignment is achieved using a computational device as described below. Each read is compared to a reference genome, which is often too large (millions of base pairs) to identify the site where the read uniquely corresponds to the reference genome. In some embodiments, the alignment procedure can limit mismatches between the read and the reference genome. In some cases, 1, 2, 3 or more base pairs in the read allow mismatches of corresponding base pairs in the reference genome, and mapping is still performed. In some embodiments, a read is considered to be an aligned read if it is aligned to a reference sequence with 1, 2, 3, or 4 base pairs or less. Correspondingly, a non-aligned read is a read that cannot be aligned or is poorly aligned. A poorly aligned read is a read that has more mismatches than an aligned read. In some embodiments, a read is considered to be an aligned read if it is aligned to a reference sequence with 1%, 2%, 3%, 4%, 5%, or 10% or less base pairs.

[0193] After aligning the paired-end reads to a reference sequence that includes the repetitive sequence of interest, process 300 identifies an anchor read and an anchored read between the paired-end reads. See block 306. As described above, an anchor read is an end read that is aligned to or near the repetitive sequence. In some embodiments, an anchor read is a paired-end read that is aligned within 1 kb of the repetitive sequence. An anchor read is paired with an anchored read, but cannot be aligned to the reference sequence or is poorly aligned to the reference sequence, as described above.

[0194] The process 300 analyzes the number of repeats of the repeat unit in the identified anchored read and / or anchored read to determine the presence or absence of an extension of the repeat sequence. More specifically, the process 300 includes using the number of repeats in the read to obtain a number of high count reads in the anchored read and / or anchored read. A high count read is a read that has more repeats than a threshold. In some embodiments, high count reads are obtained only from anchored reads. In other embodiments, high count reads are obtained from both anchored and anchored reads. In some embodiments, a read is considered a high count read if the number of repeats is close to the maximum number of repeats that can be read. For example, if the read is 100 bp and the repeat unit under consideration is 3 bp, the maximum number of repeats is 33. In other words, the maximum value is calculated from the length of the paired-end read and the length of the repeat unit. Specifically, the maximum number of repeats may be obtained by dividing the read length by the length of the repeat unit and rounding down the number. In this example, various embodiments may identify 100 bp reads having at least about 28, 29, 30, 31, 32, or 33 repeats as high count reads. The number of repeats may be adjusted upwards or downwards for high count reads based on empirical factors and considerations. In various embodiments, the threshold for high count reads is at least about 80%, 85%, 90%, or 95% of the maximum number of repeats.

[0195] Next, process 300 determines whether a repeat extension of a repetitive sequence is likely to exist based on the number of high count reads. See block 310. In some embodiments, the analysis compares the obtained high count reads to a call criterion and determines that a repeat extension is likely to exist if the criterion is exceeded. In some embodiments, the call criterion is obtained from the distribution of high count reads of a control sample. For example, a number of control samples known to have or suspected to have a common repetitive sequence are analyzed and high count reads are obtained for the control samples as above. The distribution of high count reads of the control samples can be obtained and the probability of an unaffected sample having more high count reads than a particular value can be estimated. This probability allows for the determination of sensitivity and selectivity, given the call criterion set to this particular value. In some embodiments, the call criterion is set to a threshold value such that the probability of an unaffected sample having more high count reads than the threshold is less than 5%. In other words, the p-value is less than 0.05. In these embodiments, as the repeat sequence is extended, the repeat sequence becomes longer and can occur entirely within the repeat sequence, and more high count reads can be obtained for the sample. In various alternative embodiments, a lower call criterion may be selected such that the probability of an unaffected sample having a high count read higher than the threshold is less than about 1%, 0.1%, 0.01%, 0.001%, 0.0001%, etc. It will be understood that the call criterion can be adjusted upwards or downwards based on various factors and needs to increase the sensitivity or selectivity of the test.

[0196] In some embodiments, instead of or in addition to empirically obtaining a calling criterion for the number of high-count reads from a control sample, a calling criterion may be obtained theoretically to determine repeat extensions. It is possible to calculate the expected number of reads that lie entirely within a repeat, taking into account a number of parameters, including the length of the paired-end reads, the length of the sequence with the repeat extension, and the sequencing depth. For example, the sequencing depth can be used to calculate the average spacing between reads in an aligned genome. If an individual sample is sequenced to a depth of 30x, the total bases sequenced are equal to the size of the genome multiplied by the depth. For humans, this is approximately 3x10 9 x30=9x10 10 If each read is 100bp long, a total of 9x10 8 There are 4.5 × 10 reads per haplotype. Because the genome is diploid, half of these reads sequence one chromosome / haplotype and the rest sequence the other chromosome / haplotype. 8 reads, and dividing the total genome size by this number gives the average spacing between the start positions of each read (i.e., 3x10 every 6.7 bp on average). 9 / 4.5x10 8= 1 average interval) is obtained. This number can be used to estimate the number of reads that can be completely within a repetitive sequence based on the size of that repetitive sequence in a particular individual. If the total size of the repetitive sequence is 300bp, any read that starts within the first 200bp of the repetitive sequence can be completely within the repetitive sequence (any read that starts within the last 100bp will be at least partially outside the repetitive sequence based on the read length of 100bp). Since it is expected that a read can align every 6.7bp, 200bp / (6.7bp / read) = 30 reads are expected to align completely within the repetitive sequence. Although there is variability around this number, it allows for an estimation of the total reads that can be completely within the repetitive sequence for any stretch size. The length of the repetitive sequence and the corresponding expected number of reads that are completely aligned within the repetitive sequence calculated according to this method are shown in Table 2 in Example 1 below.

[0197] In some embodiments, the call criterion is calculated from the distance between the first and last observation of a repeat sequence within a read, thus allowing for variation in repeat sequences and sequencing errors.

[0198] In some embodiments, the process may further include diagnosing the individual from whom the sample is obtained with an elevated risk of a genetic disease, such as Fragile X Syndrome, ALS, Huntington's Disease, Friedreich's Ataxia, Spinocerebellar Degeneration, Spinobulbar Muscular Atrophy, Myotonic Dystrophy, Machado-Joseph Disease, Dentatorubral-Pallidoluysian Atrophy, etc. Such a diagnosis may be based on a determination that the repeat expansion is likely to be present in the test sample and is likely to be present in the gene and in the repetitive sequence with the repeat expansion. In other embodiments, where a genetic disease is not known, some embodiments may detect an abnormally high repeat number to de novo identify the genetic cause of the disease.

[0199] FIG. 4 is a flow chart illustrating another process for detecting repeat extensions, according to some embodiments. Process 400 uses the number of repeats in paired-end reads of a test sample rather than high-count reads to determine the presence of repeat extensions. Process 400 begins by sequencing a test sample containing nucleic acid to obtain paired-end reads. See block 402, which is equivalent to block 302 in process 300. Process 400 continues by aligning the paired-end reads to a reference sequence that includes the repeat sequence. See block 404, which is equivalent to block 304 in process 300. The process proceeds by identifying anchor reads and anchored reads in the paired-end reads, where anchor reads are reads that align to or align near the repeat sequence, and anchored reads are non-aligned reads paired with the anchor read. In some embodiments, non-aligned reads include both reads that cannot be aligned to a reference sequence and reads that align poorly to a reference sequence.

[0200] After identifying anchor reads and anchored reads, process 400 obtains the number of repeats in the anchor reads and / or anchored reads from the test sample. See block 408. The process then obtains a distribution of repeat numbers for all anchor reads and / or anchored reads obtained from the test sample. In some embodiments, only the number of repeats from the anchored reads are analyzed. In other embodiments, repeats of both the anchored reads and the anchored reads are analyzed. The distribution of repeat numbers of the test sample is then compared to the distribution of one or more control samples. See block 410. In some embodiments, the process determines that a repeat expansion of a repetitive sequence is present in the test sample if the distribution of the test sample is statistically significantly different from the distribution of the control sample. See block 412. Process 400 analyzes the number of repeats of reads including high count reads as well as low count reads, which differs from processes that analyze only high count reads, such as those described above with respect to process 300.

[0201] In some embodiments, comparing the distribution of the test sample to the distribution of the control sample includes using a Mann-Whitney rank test to determine whether the two distributions are significantly different. In some embodiments, the analysis determines that a repeat expansion is more likely to be present in the test sample when the distribution of the test sample is more skewed toward higher repeat numbers relative to the control sample, and the p-value of the Mann-Whitney rank test is less than about 0.0001 or 0.00001. The p-value may be adjusted as needed to improve the selectivity or sensitivity of the test.

[0202] The process for detecting repeat expansions described above with respect to Figures 2-4 uses anchored reads, which are unaligned reads paired with reads aligned to the repeat sequences of interest. Variations of these processes can include searching through the unaligned reads of the read pairs, both composed almost entirely of some type of repeat sequence, to discover new, previously unidentified repeat expansions that may be medically relevant. The method does not quantify the exact number of repeats, but is powerful in identifying extreme repeat expansions or outliers that should be flagged for further quantification. By combining the method with longer long reads, repeats up to 200bp or more in length can be both identified and quantified.

[0203] FIG. 5 shows a flow diagram of a process 500 that uses unaligned reads that are not related to any repeat sequence of interest to identify repeat expansions. The process 500 may use unaligned reads across a genome to detect repeat expansions. The process begins by sequencing a test sample that includes nucleic acids to obtain paired-end reads. See block 502. The process 500 proceeds by aligning the paired-end reads to a reference genome. See block 504. The process then identifies unaligned reads with respect to the entire genome. Unaligned reads include paired-end reads that cannot be aligned to the reference sequence or that align poorly to the reference sequence. See block 506. The process then analyzes the number of repeats of the repeat units in the unaligned reads to determine whether a repeat expansion is likely to be present in the test sample. The analysis is agnostic to any particular repeat sequence. The analysis can be applied to a variety of potential repeat units, and the number of repeats of different repeat units from the test sample can be compared to that of multiple control samples. The above-mentioned techniques for comparison between test samples and control samples can be applied to this analysis. If the comparison indicates that the test sample has an abnormally large number of repeats of the repeat unit, additional analysis may be performed to determine whether the test sample contains a repeat expansion of the particular repeat sequence of interest. See block 510.

[0204] In some embodiments, the additional analysis includes very long sequence reads, which may span long repetitive sequences with medically relevant repeat expansions. The reads in this additional analysis are longer than paired-end reads. In some embodiments, single molecule sequencing or synthetic long-read sequencing is used to obtain the long reads. In some embodiments, the relationship between repeat expansions and genetic diseases is known in the art. However, in other embodiments, the relationship between repeat expansions and genetic diseases need not be established in the art.

[0205] In some embodiments, analyzing the number of repeats of the repeat unit in the unaligned reads in operation 510 includes a high count analysis equivalent to operation 308 in FIG. 3. The analysis includes obtaining a number of high count reads, where the high count reads are unaligned reads that have more repeats than a threshold, and comparing the number of high count reads in the test sample to a call criterion. In some embodiments, the threshold for high count reads is at least about 80% of the maximum number of repeats, where the maximum is calculated as the ratio of the length of the paired-end read over the length of the repeat unit. In some embodiments, the high count reads also include reads that are paired with unaligned reads and that are also more repetitive than the threshold.

[0206] In some embodiments, prior to the further analysis of operation 510, the process further includes (a) identifying paired-end reads that are paired with unaligned reads and that are aligned on or near the repetitive sequence on the reference genome, and (b) providing the repetitive sequence as the specific repetitive sequence of interest for operation 510. Further analysis of the repetitive sequence of interest may then employ any of the methods described above in connection with Figures 2-4. sample

[0207] The sample used to determine the repeat expansion can include samples taken from any cell, fluid, tissue, or organ that contains a nucleic acid in which the repeat expansion of one or more repeat sequences of interest is to be determined. In some embodiments involving fetal diagnosis, it is advantageous to obtain cell-free nucleic acid, e.g., cell-free DNA (cfDNA), from maternal body fluids. Cell-free nucleic acids, including cell-free DNA, can be obtained from biological samples, including plasma, serum, and urine, by a variety of methods known in the art (see, e.g., Fan et al., Proc Natl Acad Sci 105:16266-16271

[2008] ; Koide et al., Prenatal Diagnosis 25:604-607

[2005] ; Chen et al., Nature Med. 2:1033-1035

[1996] ; Lo et al., Lancet 350:485-487

[1997] ; Botezatu et al., Clin Chem. 46:1078-1084, 2000; and Su et al., J Mol. Diagn. 6:101-107

[2004] ).

[0208] In various embodiments, the nucleic acids (e.g., DNA or RNA) present in the sample can be enriched specifically or non-specifically before use (e.g., before preparing a sequencing library). DNA is used as an example of nucleic acid in the following illustrative examples. Non-specific enrichment of sample DNA refers to whole genome amplification of genomic DNA fragments of the sample, which can be used to increase the level of sample DNA before preparing a cfDNA sequencing library. Whole genome amplification methods are known in the art. Degenerate oligonucleotide-primed PCR (DOP), primer extension PCR technique (PEP), and multiple displacement amplification (MDA) are examples of whole genome amplification methods. In some embodiments, the sample is not enriched for DNA.

[0209] Samples containing nucleic acids to which the methods described herein are applied typically include biological samples ("test samples") as described above. In some embodiments, the nucleic acids to be screened for repeat expansions are purified or isolated by any of a number of known methods.

[0210] Thus, in certain embodiments, the sample comprises or consists essentially of purified or isolated polynucleotides, or the sample can comprise a tissue sample, a biological fluid sample, a cell sample, etc. Suitable biological fluid samples include, but are not limited to, blood, plasma, serum, sweat, tears, phlegm, urine, sputum, ear fluid, lymph, saliva, cerebrospinal fluid, lavage, bone marrow suspension, vaginal flow, cervical fluid, femoral neck fluid, brain fluid, peritoneal fluid, milk, secretions of the respiratory, intestinal and genitourinary tracts, amniotic fluid, milk, and leukocytapheresis samples. In some embodiments, the sample is a sample that can be readily obtained by a non-invasive procedure, such as, for example, blood, plasma, serum, sweat, tears, phlegm, urine, sputum, ear fluid, saliva, or feces. In certain embodiments, the sample is a peripheral blood sample, or a plasma and / or serous fraction of a peripheral blood sample. In other embodiments, the biological sample is a swab or smear, a biopsy specimen, or a cell culture. In another embodiment, the sample is a mixture of two or more biological samples, for example, the biological sample can include two or more of a biological fluid sample, a tissue sample, and a cell culture sample. As used herein, the terms "blood," "plasma," and "serum" expressly include fractions thereof or processed portions thereof. Similarly, if a sample is taken from a biopsy, swab, smear, etc., the "sample" expressly includes processed fractions or portions obtained from the biopsy, swab, smear, etc.

[0211] In certain embodiments, samples include, but are not limited to, samples from different individuals, samples from different developmental stages of the same individual or different individuals, samples from different diseased individuals (e.g., individuals suspected of having a genetic disease), normal individuals, samples obtained at different stages of a disease in an individual, samples obtained from individuals receiving different treatments for a disease, samples from individuals exposed to different environmental factors, samples from individuals predisposed to a disease condition, samples from individuals exposed to an infectious agent, etc.

[0212] In one exemplary but non-limiting embodiment, the sample is a maternal sample obtained from a pregnant woman, e.g., a pregnant woman. In this case, the sample can be analyzed using the methods described herein to provide an early diagnosis of potential chromosomal abnormalities in the fetus. The maternal sample can be a tissue sample, a biological fluid sample, or a cell sample. Biological fluids include, by way of non-limiting example, blood, plasma, serum, sweat, tears, sputum, urine, sputum, ear fluid, lymphatic fluid, saliva, cerebrospinal fluid, lavage, bone marrow suspension, vaginal flow, cervical fluid, femoral neck fluid, brain fluid, ascites, milk, secretions of the respiratory tract, intestinal tract and urogenital tract, and leukapheresis samples.

[0213] In certain embodiments, samples can also be obtained from in vitro cultured tissues, cells, or other polynucleotide-containing sources. Cultured samples can be taken from sources including, but not limited to, cultures (e.g., tissues or cells) maintained in different media and conditions (e.g., pH, pressure, or temperature), cultures (e.g., tissues or cells) maintained for different time periods, cultures (e.g., tissues or cells) treated with different factors or reagents (e.g., drug candidates, or modulators), or cultures of different types of tissues and / or cells.

[0214] Methods for isolating nucleic acid from biological sources are known and may vary depending on the nature of the source. Those skilled in the art can easily separate nucleic acid from the source as required for the methods described herein. In some cases, it may be advantageous to fragment the nucleic acid molecules in the nucleic acid sample. Fragmentation may be random or specific, for example, as achieved using restriction endonuclease digestion. Methods for random fragmentation are known in the art and include, for example, limited DNAse digestion, alkaline treatment, and physical shearing. Sequencing library preparation

[0215] In various embodiments, sequencing may be performed on various sequencing platforms requiring preparation of a sequencing library. Preparation typically involves fragmenting the DNA (sonication, nebulization or shearing), followed by DNA repair and end polishing (blunt ends or A-overhangs), and platform-specific adaptor ligation. In one embodiment, the methods described herein can utilize next-generation sequencing technology (NGS), which allows multiple samples to be sequenced individually as genomic molecules (i.e., singleplex sequencing) or individually as pooled samples containing indexed genomic molecules on a single sequencing run (e.g., multiplex sequencing). These methods can generate up to millions of DNA sequence reads. In various embodiments, the genomic nucleic acid sequence and / or the sequence of the indexed genomic nucleic acid can be determined, for example, using next-generation sequencing technology (NGS) described herein. In various embodiments, analysis of the large amount of sequence data obtained using NGS can be performed using one or more processors as described herein.

[0216] In various embodiments, the use of such sequencing techniques does not involve the preparation of a sequencing library.

[0217] However, in certain embodiments, the sequencing methods contemplated herein include the preparation of a sequencing library. In one exemplary approach, the preparation of a sequencing library includes the generation of a random collection of adaptor-modified DNA fragments (e.g., polynucleotides) ready to be sequenced. A sequencing library of polynucleotides can be prepared from DNA or RNA, including equivalents, analogs of either DNA or cDNA, such as DNA or cDNA that is a complementary or copy DNA generated from an RNA template, for example, by the action of reverse transcriptase. Polynucleotides can occur in double-stranded form (e.g., dsDNA such as genomic DNA fragments, cDNA, PCR amplification products, etc.), or in certain embodiments, polynucleotides can occur in single-stranded form (e.g., ssDNA, RNA, etc.) and have been converted to a dsDNA form. By way of example, in certain embodiments, single-stranded mRNA molecules can be copied into double-stranded cDNA suitable for use in the preparation of a sequencing library. The exact sequence of the primary polynucleotide molecule is generally not important to the method of library preparation and may be known or unknown. In one embodiment, the polynucleotide molecule is a DNA molecule. More specifically, in certain embodiments, the polynucleotide molecule represents the entire gene complement of an organism or substantially the entire gene complement of an organism, and is a genomic DNA molecule (e.g., cellular DNA, cell-free DNA (cfDNA), etc.), but typically includes intron and exon sequences (coding sequences), as well as non-coding regulatory sequences such as promoter and enhancer sequences. In certain embodiments, the primary polynucleotide molecule includes a human genomic DNA molecule, e.g., a cfDNA molecule present in the peripheral blood of a pregnant subject.

[0218] Preparation of sequencing libraries for some NGS sequencing platforms is facilitated by the use of polynucleotides that contain a specific range of fragment sizes. Preparation of such libraries typically involves fragmentation of larger polynucleotides (e.g., cellular genomic DNA) to obtain polynucleotides within a desired size range for determining repeat extensions.

[0219] The length of the fragment or insert is longer than the read length, typically longer than the sum of the lengths of the two reads.

[0220] In some exemplary embodiments, the sample nucleic acid(s) are obtained as genomic DNA, which is fragmented into fragments of about 100 or more, about 200 or more, about 300 or more, about 400 or more, or about 500 or more base pairs, allowing for easy application of NGS methods. In some embodiments, paired-end reads are obtained from inserts of about 100-5000 bp. In some embodiments, the inserts are about 100-1000 bp in length. These may be performed as regular short-insert paired-end reads. In some embodiments, the inserts are about 1000-5000 bp in length. These may be performed as long-insert mate-pair reads, as described above.

[0221] In some embodiments, long inserts are designed to evaluate very long, extended repeat sequences. In some embodiments, mate-pair reads may be applied to obtain reads that are spaced apart by thousands of base pairs. In these runs, the inserts or fragments range from hundreds to thousands of base pairs, and there are two biotin-binding adapters on the two ends of the insert. The biotin-binding adapters then join the two ends of the insert to form a circularized molecule, which is further fragmented. The subfragments containing the biotin-binding adapters, and the two ends of the original insert, are selected for sequencing on a platform designed to sequence shorter fragments.

[0222] Fragmentation can be achieved by any of a number of methods known to those skilled in the art. For example, fragmentation can be achieved by mechanical means, including but not limited to nebulization, sonication, and hydroshear. However, mechanical fragmentation typically cleaves the DNA backbone at CO, PO, and CC bonds, resulting in a heterogeneous mixture of blunt and 3'-overhanging and 5'-overhanging ends with missing CO, PO, and CC bonds (see, e.g., Alnemri and Liwack, J Biol. Chem 265:17323-17333

[1990] ; Richards and Boyer, J Mol Biol 11:327-240

[1965] ), which may need to be repaired because they are missing the essential 5'-phosphate for subsequent enzymatic reactions (e.g., ligation of sequencing adaptors required to prepare DNA for sequencing).

[0223] In contrast, cfDNA typically exists as fragments of less than about 300 base pairs, and as a result, fragmentation is not typically necessary to generate a sequencing library using a cfDNA sample.

[0224] Typically, whether polynucleotides are forcibly fragmented (e.g., fragmented in vitro) or naturally present as fragments, they are converted to blunt-ended DNA with a 5'-phosphate and a 3'-hydroxyl. Standard protocols, such as those for sequencing using the Illumina platform as described elsewhere herein, instruct users to purify the end-repaired product prior to dA-tailing for end-repaired sample DNA, and to purify the dA-tailed product prior to the adapter-ligating step of library preparation.

[0225] Various embodiments of the method for preparing a sequence library described herein eliminate the need to perform one or more of the steps typically prescribed by standard protocols to obtain modified DNA products that can be sequenced by NGS. The abbreviated method (ABB method), one-step method, and two-step method are examples of the method for preparing a sequence library that can be found in patent application Ser. No. 13 / 555,037 (filed Jul. 20, 2012), the entirety of which is incorporated herein by reference. Sequencing Methods

[0226] As described above, the prepared samples (e.g., sequencing libraries) are sequenced as part of the procedure to identify copy number alterations. Any of a number of sequencing technologies can be utilized.

[0227] Several sequencing technologies are commercially available, such as the sequencing-by-hybridization platform from Affymetrix Inc. (Sunnyvale, Calif.), and sequencing-by-synthesis platforms from 454 Life Sciences (Bradford, Conn.), Illumina / Solexa (San Diego, Calif.), and Helicos Biosciences (Cambridge, Mass.), as well as the sequencing-by-ligation platform from Applied Biosystems (Foster City, Calif.), as described below. In addition to single molecule sequencing performed using Helicos Biosciences' sequencing-by-synthesis, other single molecule sequencing technologies include Pacific Biosciences' SMRT™ technology, ION TORRENT™ technology, and ION ATRON™ technology. 、and nanopore sequencing, for example and without limitation, developed by Oxford Nanopore Technologies.

[0228] Although the automated Sanger method is considered to be a "first generation" technology, Sanger sequencing, including automated Sanger sequencing, can also be employed in the methods described herein.Further suitable sequencing methods include, but are not limited to, nucleic acid imaging techniques, such as atomic force microscopy (AFM) or transmission electron microscopy (TEM).Exemplary sequencing techniques are described in more detail below.

[0229] In some embodiments, the disclosed methods include obtaining sequence information about nucleic acids in a test sample by massively parallel sequencing of millions of DNA fragments using Illumina's (e.g., as described in Bentley et al., Nature 6:53-59

[2009] ) sequencing synthesis and reversible terminator-based sequencing chemistry. The template DNA can be genomic DNA, e.g., cellular DNA or cfDNA. In some embodiments, genomic DNA from isolated cells is used as a template and fragmented to lengths of several hundred base pairs. In other embodiments, cfDNA is used as a template, but fragmentation is not required since cfDNA exists as short fragments. For example, fetal cfDNA circulates in the bloodstream as fragments of about 170 base pairs (bp) in length (Fan et al., Clin Chem 56:1279-1286

[2010] ), and does not require DNA fragmentation prior to sequencing. Illumina's sequencing technology relies on the attachment of fragmented genomic DNA to a planar, optically transparent surface to which an oligonucleotide anchor is attached. The template DNA is end-repaired to generate 5' phosphorylated blunt ends, and the polymerase activity of the Klenow fragment is used to add a single A base to the 3' ends of the blunt phosphorylated DNA fragments. This addition prepares the DNA fragments for ligation to oligonucleotide adapters that have a single T base overhang at their 3' ends to increase ligation efficiency. The adapter oligonucleotides are complementary to the anchor oligos of the flow cell (not to be confused with anchored / anchored reads in the analysis of repeat extension). Under limiting dilution conditions, the adapter-modified single-stranded template DNA is added to the flow cell to be fixed to the anchor oligo by hybridization. The attached DNA fragments are extended and the bridges are amplified to create an ultra-high density sequencing flow cell with hundreds of millions of clusters, each containing approximately 1,000 copies of the same template. In one embodiment, the randomly fragmented genomic DNA is amplified using PCR before undergoing cluster amplification.Alternatively, an unamplified genomic library preparation is used, and randomly fragmented genomic DNA is enriched using cluster amplification only (Kozarewa et al., Nature Methods 6:291-295

[2009] ). Templates are sequenced using robust four-color DNA sequencing-by-synthesis technology, which employs reversible terminators with removable fluorescent dyes. Highly sensitive fluorescence detection is achieved using laser excitation and total internal reflection optics. Short sequence reads of about tens to hundreds of base pairs are aligned against a reference genome, and unique mapping of the short sequence reads to the reference genome is identified using specially developed data analysis pipeline software. After the first read is completed, the template can be regenerated in situ to allow a second read from the opposite end of the fragment. Thus, either single-end or paired-end sequencing of DNA fragments can be used.

[0230] Various embodiments of the present disclosure may use sequencing by synthesis, which allows paired-end sequencing. In some embodiments, the Illumina sequencing by synthesis platform includes clustered fragments. Clustering is a process in which each fragment molecule is isothermally amplified. In some embodiments, as an example described herein, the fragments have two different adapters attached to the two ends of the fragment, which allow the fragments to hybridize with two different oligos on the surface of the flow cell lane. The fragments further include or are connected to two index sequences at the two ends of the fragment, which provide labels to identify different samples in multiplex sequencing. In some sequencing platforms, the fragments to be sequenced are also called inserts.

[0231] In some embodiments, a flow cell for clustering in the Illumina platform is a glass slide with lanes. Each lane is a glass channel coated with a lawn of two oligos. Hybridization is enabled by the first of the two oligos on the surface. This oligo is complementary to the first adapter at one end of the fragment. A polymerase generates the complementary strand of the hybrid fragment. The double-stranded molecule is denatured and the original template strand is washed away. The remaining strand is clonally amplified by bridge application in parallel with many other remaining strands.

[0232] In bridge amplification, a second adapter region on the second end of the strand hybridizes to a second type of oligo on the flow cell surface. A polymerase generates a complementary strand, forming a double-stranded bridge molecule. This double-stranded molecule is denatured, resulting in two single-stranded molecules tethered to the flow cell via two different oligos. The process is then repeated across millions of clusters, which occur simultaneously, resulting in clonal amplification of all fragments. After bridge amplification, the reverse strand is cleaved and washed, leaving only the forward strand. The 3' end is blocked to prevent undesired priming.

[0233] After clustering, sequencing begins by extending the first sequencing primer to generate the first read. In each cycle, fluorescently labeled nucleotides compete to add to the growing strand. Only one is incorporated based on the sequence of the template. After each nucleotide addition, the cluster is excited by a light source and a characteristic fluorescent signal is emitted. The number of cycles determines the length of the read. The emission wavelength and signal intensity determine the base call. For a given cluster, all identical strands are read simultaneously. Hundreds of millions of clusters are sequenced in a massively parallel fashion. Upon completion of the first read, the read products are washed out.

[0234] In the next step of the protocol, which includes two index primers, the index 1 primer is introduced and hybridizes to the index 1 region on the template. The index region provides fragment identification useful for demultiplexing samples in the multiplex sequencing process. The index 1 read is generated similarly to the first read. After the index 1 read is complete, the read product is washed away and the 3' end of the strand is deprotected. The template strand then folds over the second oligo on the flow cell and binds to the second oligo. The index 2 sequence is read in the same manner as index 1. The index 2 read product is then washed away upon completion of the step.

[0235] After reading the two indices, a polymerase is used to initiate read 2, extending the second flow cell oligo to form a double-stranded bridge. This double-stranded DNA is denatured and the 3' end is blocked. The original forward strand is cleaved and washed away, leaving the reverse strand. Read 2 begins with the introduction of the read 2 sequencing primer. As with read 1, the sequencing steps are repeated until the desired length is achieved. The read 2 product is washed away. This entire process generates millions of reads, representing all fragments. Sequences from the pooled sample library are separated based on the unique indices introduced during sample preparation. For each sample, reads of similar extension base calls are locally clustered. Forward and reverse reads are paired to create contiguous sequences. These contiguous sequences are aligned to the reference genome for variant identification.

[0236] Sequencing by synthesis example above includes paired-end reads, which are used in many embodiments of the disclosed methods. Paired end sequences include two reads from the two ends of a fragment. Paired-end reads are used to resolve ambiguous alignments. Paired-end sequencing allows the user to select the length of the insert (or fragment to be sequenced) and sequence either end of the insert, generating high-quality alignable sequence data. Because the distance between each paired read is known, the alignment algorithm can use this information to more precisely position the reads on repetitive regions. This results in better alignment of reads, especially across difficult-to-sequence repetitive regions of the genome. Paired-end sequencing can detect insertions and deletions (indels) as well as rearrangements, including inversions.

[0237] Paired-end reads may use inserts of different lengths (i.e., different fragment sizes to be sequenced). As a default meaning in this disclosure, paired-end reads are used to mean reads obtained from various insert lengths. In some cases, to distinguish short-insert paired-end reads from long-insert paired-end reads, the latter are specifically referred to as mate-paired reads. In some embodiments involving mate-paired reads, first, two biotin-binding adapters are attached to the two ends of a relatively long insert (e.g., several kb). Then, the biotin-binding adapters link the two ends of the insert to form a circular molecule. Then, subfragments that include the biotin-binding adapters can be obtained by further fragmenting the circular molecule. Then, the subfragments that include the two ends of the original fragment in the opposite order can be sequenced by the same procedure as the short-insert paired-end sequencing described above. Further details on mate-pair sequencing using the Illumina platform are provided in an online publication at the following address, which is incorporated herein by reference in its entirety: res.illumina.com / documents / products / technotes / technote_nextera_matepair_data_processing.pdf

[0238] After sequencing the DNA fragments, sequence reads of a given length (e.g., 100 bp) are mapped or aligned to a known reference genome. The mapped or aligned reads and their corresponding positions on the reference sequence are also called tags. The analysis of many embodiments disclosed herein for determining repeat extensions uses poorly aligned or unaligned reads as well as aligned reads (tags). In one embodiment, the reference genome sequence is the NCBI36 / hg18 sequence, available on the World Wide Web (www) at genome.ucsc.edu / cgi-bin / hgGateway?org=Human&db=hg18&hgsid=166260105. Alternatively, the reference genome sequence is GRCh37 / hg19, available on the World Wide Web (www) at genome.ucsc.edu / cgi-bin / hgGateway. Other sources of public sequence information include GenBank, dbEST, dbSTS, EMBL (the European Molecular Biology Laboratory), and DDBJ (Japan DNA Database). Numerous computer algorithms for aligning sequences are available, including but not limited to BLAST (Altschul et al., 1990), BLITZ (MPsrch) (Sturrock & Collins, 1993), FASTA (Person & Lipman, 1988), BOWTIE (Langmead et al., Genome Biology 10:R25.1-R25.10

[2009] ), or ELAND (Illumina, Inc., San Diego, CA, USA). In one embodiment, one end of the clonal extension copy of the plasma cfDNA molecule is aligned and processed by gene informatic alignment analysis on an Illumina Genome Analyzer using Efficient Large-Scale Alignment of Nucleotide Databases (ELAND) software.

[0239] In one exemplary, but non-limiting embodiment, the methods described herein include obtaining sequence information about nucleic acids in a test sample using single molecule sequencing technology, such as Helicos True Single Molecule Sequencing (tSMS) technology (e.g., as described in Harris TD et al., Science 320:106-109

[2008] ). In the tSMS technology, a DNA sample is sheared into strands of about 100-200 nucleotides and a polyA sequence is added to the 3' end of each DNA strand. Each strand is labeled by the addition of fluorescently labeled adenosine nucleotides. The DNA strands are then hybridized to a flow cell, which contains millions of oligo-T capture sites immobilized on the flow cell surface. In certain embodiments, the templates are quantified at about 100 million templates / cm. 2 The flow cell can then be added to an instrument, for example a HeliScope™ sequencer, and a laser is shone on the surface of the flow cell to reveal the location of each template. A CCD camera can locate the location of the template on the surface of the flow cell. The template fluorescent label is then cleaved and washed away. The sequencing reaction is initiated by introducing a DNA polymerase and a fluorescently labeled nucleotide. The oligo-T nucleic acid serves as a primer. The polymerase incorporates the labeled nucleotide into the primer in a template-guided manner. The polymerase and the unincorporated nucleotide are removed. Templates with induced incorporation of the fluorescently labeled nucleotide are identified by imaging the surface of the flow cell. After imaging, a cleavage step removed the fluorescent label. This process is repeated with other fluorescently labeled nucleotides until the desired read length is achieved. Sequence information is collected with each nucleotide addition step. Whole genome sequencing by single molecule sequencing technology precludes or typically eliminates PCR-based amplification in the preparation of the sequencing library, and the method allows for direct measurement of the sample, rather than measurement of copies of that sample.

[0240] In another exemplary but non-limiting embodiment, the methods described herein include obtaining sequence information about nucleic acids in a test sample using 454 sequencing (Roche) (e.g., as described in Margulies, M. et al. Nature 437:376-380

[2005] ). 454 sequencing typically involves two steps. In the first step, DNA is sheared into fragments of about 300-800 base pairs, and the fragments are blunt ended. Oligonucleotide adaptors are then ligated to the ends of the fragments. The adaptors serve as primers for amplification and sequencing of the fragments. The fragments can be attached to DNA capture beads, e.g., streptavidin-coated beads, e.g., using adaptor B, which contains a 5' biotin tag. The fragments attached to the beads are PCR amplified within droplets of an oil-in-water emulsion. The result is multiple copies of clonally amplified DNA fragments on each bead. In a second step, the beads are captured in wells (e.g. picoliter-sized wells). Pyrosequencing is performed in parallel for each DNA fragment. The addition of one or more nucleotides generates a light signal that is recorded by a CCD camera in the sequencing instrument. The signal intensity is proportional to the number of nucleotides incorporated. Pyrosequencing uses pyrophosphate (PPi), which is released upon addition of a nucleotide. PPi is converted to ATP by ATP sulfurylase in the presence of adenosine 5' phosphosulfate. Luciferase uses ATP to convert luciferin to oxyluciferin, a reaction that generates light that is measured and analyzed.

[0241] In another exemplary but non-limiting embodiment, the methods described herein include obtaining sequence information about nucleic acids in a test sample using SOLiD™ technology (Applied Biosystems). SOLiD™ sequencing by ligation involves shearing genomic DNA into fragments and attaching adapters to the 5' and 3' ends of the fragments to generate a fragment library. Alternatively, internal adapters can be introduced by ligating adapters to the 5' and 3' ends of the fragments, circularizing the fragments, digesting the circularized fragments to generate internal adapters, and attaching adapters to the 5' and 3' ends of the resulting fragments to generate a mate-pair library. A clonal bead population is then prepared in a microreactor containing beads, primers, templates, and PCR components. After PCR, the templates are denatured and the beads are enriched to separate the beads from the extended templates. Templates on selected beads undergo a 3' modification that allows for attachment to a glass slide. The sequence can be determined by sequential hybridization and ligation of partially random oligonucleotides with a central determining base (or base pair) that is specified by a particular fluorophore. After the color is recorded, the ligated oligonucleotide is cleaved and removed, and the process is then repeated.

[0242] In another exemplary but non-limiting embodiment, the method described herein includes obtaining sequence information about nucleic acids in a test sample using Pacific Biosciences' single molecule, real-time (SMRT™) sequencing technology. In SMRT sequencing, the sequential incorporation of dye-labeled nucleotides is imaged during DNA synthesis. Single DNA polymerase molecules are attached to the bottom of individual zero-mode wavelength detectors (ZMW detectors) that obtain sequence information, while phospho-linked nucleotides are incorporated into the growing primer strand. The ZMW detectors contain a constraining structure that allows observation of the incorporation of a single base by the DNA polymerase against a background of fluorescent nucleotides that rapidly diffuse (e.g., in microseconds) out of the ZMW. It typically takes several milliseconds to incorporate a nucleotide into the growing strand. At this time, the fluorescent label is excited, generating a fluorescent signal, and the fluorescent label is cleaved. Measurement of the corresponding fluorescence of the dye indicates which base has been incorporated. The process is repeated to provide the sequence.

[0243] In another exemplary but non-limiting embodiment, the methods described herein include obtaining sequence information about nucleic acids in a test sample using nanopore sequencing (e.g., as described in Soni GV and Meller A. Clin Chem 53:1996-2001

[2007] ). Nanopore sequencing DNA analysis technology is developed by a number of companies, including, for example, Oxford Nanopore Technologies (Oxford, United Kingdom), Sequenom, NABsys, and others. Nanopore sequencing is a single molecule sequencing technique in which a single molecule of DNA is directly sequenced as it passes through a nanopore. Nanopores are small holes, typically on the order of one nanometer in diameter. When the nanopore is immersed in a conductive fluid and a potential (voltage) is applied, a small current is generated due to the conduction of ions through the nanopore. The amount of current that flows is sensitive to the size and shape of the nanopore. As a DNA molecule passes through a nanopore, each nucleotide on the DNA molecule obstructs the nanopore to a different extent and changes the magnitude of the current through the nanopore to a different extent, and therefore this change in current as the DNA molecule passes through the nanopore provides a DNA sequence read.

[0244] In another exemplary but non-limiting embodiment, the methods described herein include obtaining sequence information about nucleic acids in a test sample using a chemical-sensitive field effect transistor (chemFET) array (described in U.S. Patent Publication No. 2009 / 0026082). In one example of this technology, DNA molecules can be placed in a reaction chamber and template molecules can be hybridized to a sequencing primer bound to a polymerase. Incorporation of one or more triphosphates into a new nucleic acid strand at the 3' end of the sequencing primer can be identified as a change in current by the chemFET. The array can have multiple chemFET sensors. In another example, a single nucleic acid can be attached to a bead, the nucleic acid can be amplified on the bead, and individual beads can be transferred to individual reaction chambers on a chemFET array, each chamber having a chemFET sensor, and the nucleic acid can be sequenced.

[0245] In another embodiment, the DNA sequencing technology is Ion Torrent single molecule sequencing, which pairs semiconductor technology with a single sequencing chemistry to directly translate chemically coded information (A, C, G, T) into digital information (0, 1) on a semiconductor chip. Essentially, when a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released as a by-product. Ion Torrent uses a high density array of micromachined wells to perform this biochemical process in a massively parallel fashion. Each well holds a different DNA molecule. Beneath the well is an ion-sensitive layer, but below the ion sensor. When a nucleotide, say C, is added to a DNA template and then incorporated into a strand of DNA, a hydrogen ion is released. The charge from this ion can change the pH of the solution, which can be detected by Ion Torrent's ion sensor. The sequencer (which is essentially the world's smallest solid-state pH meter) calls the bases and goes directly from chemical information to digital information. The Ion personal Genome Machine (PGM™) sequencer then bathes the chip with one nucleotide after another. If the next nucleotide that flows through the chip does not match, no voltage change is recorded and the base is not called. If there are two identical bases on the DNA strand, the voltage will be doubled and the chip will record the two identical bases called. Direct detection allows for the recording of nucleotide incorporation in seconds.

[0246] In another embodiment, the method includes obtaining sequence information of nucleic acids in a test sample using sequencing by hybridization. Sequencing by hybridization includes contacting a plurality of polynucleotide sequences with a plurality of polynucleotide probes, each of which may be optionally tethered to a substrate. The substrate may be a flat surface that includes an array of known nucleotide sequences. The pattern of hybridization to the array can be used to determine the polynucleotide sequences present in the sample. In other embodiments, each probe is tethered to a bead, such as a magnetic bead. Hybridization to the beads can be determined and used to identify a plurality of polynucleotide sequences in the sample.

[0247] In some embodiments of the methods described herein, the sequence reads are about 20bp, about 25bp, about 30bp, about 35bp, about 40bp, about 45bp, about 50bp, about 55bp, about 60bp, about 65bp, about 70bp, about 75bp, about 80bp, about 85bp, about about 90bp, about 95bp, about 100bp, about 110bp, about 120bp, about 130, about 140bp, about 150bp, about 200bp, about 250bp, about 300bp, about 350bp, about 400bp, about 450bp, or about 500bp. It is anticipated that technological advances will enable single-end reads of greater than 500bp, and, when paired-end reads are generated, will enable reads of greater than about 1000bp. In some embodiments, paired-end reads are used to determine repeat extensions, including sequence reads that are about 20 bp to 1000 bp, about 50 bp to 500 bp, or about 80 bp to 150 bp. In various embodiments, paired-end reads are used to evaluate sequences with repeat extensions. The sequence with repeat extensions is longer than the read. In some embodiments, the sequence with repeat extensions is longer than about 100 bp, 500 bp, 1000 bp, or 4000 bp. Mapping of sequence reads is accomplished by comparing the sequence of the read to a reference sequence to determine the chromosomal origin of the sequenced nucleic acid molecule, and no specific gene sequence information is required. Small mismatches (0 to 2 mismatches per read) can account for trace polymorphisms that may exist between the reference genome and the genome in the mixed sample. In some embodiments, reads that are aligned to the reference sequence are used as anchor reads, and are paired with the anchor reads, while reads that cannot be aligned to the reference sequence or that are poorly aligned to the reference sequence are used as anchored reads. In some embodiments, poorly aligned reads may have a relatively high percentage of mismatches per read, for example, at least about 5%, at least about 10%, at least about 15%, or at least about 20% mismatches per read.

[0248] Multiple sequence tags (i.e., reads aligned to a reference sequence) are typically obtained per sample. In some embodiments, at least about 3×10 6 sequence tags, at least about 5 × 10 6 sequence tags, at least about 8 × 10 6 sequence tags, at least about 10 × 10 6 sequence tags, at least about 15 × 10 6 sequence tags, at least about 20 × 10 6 sequence tags, at least about 30 × 10 6 sequence tags, at least about 40 × 10 6 or at least about 50×10 6 sequence tags are obtained from mapping the reads to the reference genome per sample. In some embodiments, all sequence reads are mapped to the entire region of the reference genome to provide a genome-wide read. In other embodiments, they are mapped to a sequence of interest, such as a chromosome, a segment of a chromosome, or a repeat sequence of interest. Apparatus and system for determining repeat expansions

[0249] Analysis of sequencing data and diagnostics derived therefrom is typically performed using various computer-implemented algorithms and programs. Thus, certain embodiments employ processes involving data stored in or transferred through one or more computer systems or other processing systems. The embodiments disclosed herein also relate to apparatus for performing these operations. The apparatus may be specially constructed for the required purpose or may be a general-purpose computer (or group of computers) selectively activated or reconfigured by computer programs and / or data structures stored in the computer. In some embodiments, a group of processors performs some or all of the recited analytical operations in cooperation (e.g., via a network or cloud computing) and / or in parallel. Processors or groups of processors for performing the methods described herein may be of various types, including microcontrollers and microprocessors, such as programmable devices (e.g., CPLDs and FPGAs), as well as non-programmable devices, such as gate array ASICs or general-purpose microprocessors.

[0250] One embodiment provides a system for use in genotyping variants at genomic loci comprising repetitive sequences, the system including a sequencer for receiving a nucleic acid sample and providing nucleic acid sequence information from the sample; a processor; and a machine-readable storage medium having stored thereon instructions for execution on the processor to genotype variants, wherein the variants are genotyped by: (a) collecting nucleic acid sequence reads for a test sample from a database; (b) aligning the sequence reads to one or more repetitive sequences, each represented by a sequence graph, the sequence graph having a data structure of a directed graph with vertices representing nucleic acid sequences and directed edges connecting the vertices, the sequence graph comprising one or more self-loops, each self-loop representing a repetitive subsequence, each repetitive subsequence comprising repeats of one or more nucleotide repeat units; and (c) determining one or more genotypes for the one or more repetitive sequences using the sequence reads aligned to the one or more repetitive sequences.

[0251] In some embodiments of any of the systems provided herein, the sequencer is configured to perform next generation sequencing (NGS). In some embodiments, the sequencer is configured to perform massively parallel sequencing using sequence-by-synthesis with reversible dye terminators. In other embodiments, the sequencer is configured to perform sequencing-by-ligation. In yet other embodiments, the sequencer is configured to perform single molecule sequencing.

[0252] Additionally, certain embodiments relate to tangible and / or non-transitory computer-readable media or computer program products that include program instructions and / or data (including data structures) for performing various computer-implemented operations. Examples of computer-readable media include, but are not limited to, semiconductor memory devices, magnetic media such as disk drives, magnetic tape, optical media (CDs, magneto-optical media, etc.), and hardware devices specially configured to store and execute program instructions, such as read-only memory devices (ROM) and random access memories (RAM). Computer-readable media may be directly controlled by an end user, or the media may be indirectly controlled by an end user. Examples of directly controlled media include media located at user premises and / or media that is not shared with other components. Examples of indirectly controlled media include media that is indirectly accessible to a user via an external network and / or via a service that provides shared resources, such as the "cloud". Examples of program instructions include both machine code, such as that produced by a compiler, and files that include higher level code than can be executed by a computer using an interpreter.

[0253] In various embodiments, data or information used in the disclosed methods and devices is provided in electronic format. Such data or information may include reads and tags derived from nucleic acid samples, reference sequences (including reference sequences providing solely or primarily polymorphisms), repeat extension calls, counseling recommendations, diagnosis, and other calls. When used in the present invention, data or other information provided in electronic form is available for storage on a machine and transmission between machines. Traditionally, data in electronic form is provided digitally and may be stored as bits and / or bytes in various data structures, lists, databases, and the like. Data may be embodied electronically, optically, and the like.

[0254] One embodiment provides a computer program product for generating an output indicative of the presence or absence of a repeat extension in a test sample. The computer product may include instructions for performing any one or more of the above methods for determining a repeat extension. As described, the computer product may include a non-transitory and / or tangible computer readable medium having computer executable or compilable logic (e.g., instructions) recorded thereon, which allows a processor to determine the anchor read and the repeats in the anchored read, and whether a repeat extension is present or absent. In one example, the computer product includes a computer readable medium having computer executable or compilable logic (e.g., instructions) recorded thereon for enabling a processor to diagnose a repeat extension, which includes a receiving procedure for receiving sequencing data from at least a portion of a nucleic acid molecule from an alignment to a repeat sequence, computer-assisted logic for analyzing the received data for a repeat extension, and an output procedure for generating an output indicative of the presence or absence or type of the repeat extension.

[0255] Sequence information from the sample under consideration can be mapped to chromosomal repetitive sequences to identify paired-end reads aligned or anchored to the repetitive sequences of interest and to identify repeat expansions of the repetitive sequences. In various embodiments, the reference sequences are stored in a database, such as a relational database or an object database.

[0256] It should be understood that it is not practical, or even impossible in most cases, for a human to perform the computational operations of the methods disclosed herein without assistance. For example, mapping a single 30 bp read from a sample to any one of the human chromosomes may require a great deal of effort without the assistance of a computing device. Of course, the problem is complicated because a reliable repeat extension call typically requires mapping thousands (e.g., at least about 10,000) or even millions of reads to one or more chromosomes.

[0257] In various embodiments, the raw sequence reads are aligned to one or more sequence graphs representing one or more sequences of interest. In various embodiments, at least 10,000, 100,000, 500,000, 1,000,000, 5,000,000, or 10,000,000 reads are aligned to one or more sequence graphs. In various embodiments, the one or more sequence graphs include at least 1, 2, 5, 10, 50, 100, 500, 1000, 5,000, 10,000, or 50,000 sequence graphs.

[0258] In some embodiments, raw sequence reads are first aligned to a reference genome to determine genomic coordinates of the reads before a subset of the initially aligned reads are aligned to one or more sequence graphs representing one or more sequences of interest. In various embodiments, at least 10,000, 100,000, 500,000, 1,000,000, 5,000,000, 10,000,000, or 100,000,000 reads are first aligned to the reference genome. In some embodiments, the initially aligned reads are realigned to a sequence graph to determine repeat expansions in multiple regions (each region corresponding to a sequence graph). The total number of reads realigned to a sequence graph during each implementation of an embodiment can range from thousands to millions of reads. In various embodiments, in the 10,000,000 range, reads are realigned to each sequence graph. In various embodiments, the one or more sequence graphs include at least 1, 2, 5, 10, 50, 100, 500, 1000, 5,000, 10,000, or 50,000 sequence graphs.

[0259] 5 The methods disclosed herein may be implemented using a system for genotyping variants at genomic loci that contain repetitive sequences. The system may include (a) a sequencer for receiving nucleic acids from a test sample that provides nucleic acid sequence information from the sample; (b) a processor; and (c) one or more computer-readable storage media having instructions stored thereon for performing, on the processor, genotyping variants at genomic loci that contain repetitive sequences. In some embodiments, the method is instructed by a computer-readable medium having computer-readable instructions stored thereon for performing a method for identifying any repeat expansions. Thus, one embodiment provides a computer program product including a non-transitory machine-readable medium that stores program code that, when executed by one or more processors of a computer system, causes the computer system to perform a method for identifying repeat expansions of repetitive sequences in a test sample that contains nucleic acids, the repetitive sequences comprising repeats of repeating units of nucleotides. The program code may include: (a) code for collecting sequence reads for a test sample from a database; (b) code for aligning the sequence reads to one or more repeat sequences, each represented by a sequence graph, the sequence graph having a directed graph data structure with vertices representing nucleic acid sequences and directed edges connecting the vertices, the sequence graph including one or more self-loops, each self-loop representing a repetitive subsequence, each repetitive subsequence including repeats of one or more nucleotide repeat units; and (c) code for determining one or more genotypes for the one or more repeat sequences using the sequence reads aligned to the one or more repeat sequences.

[0260] In some embodiments, the instructions may further include automatically recording information related to the method, such as repeat reads and anchored reads, and the presence or absence of repeat expansions in a patient medical record of the human subject providing the test sample. The patient medical record may be maintained, for example, by a laboratory, a physician's office, a hospital, a health maintenance organization, an insurance company, or a personal medical record. The method may further include prescribing, initiating, and / or modifying treatment for the human subject from whom the test sample was taken. This may include performing one or more additional tests or analyses on additional samples taken from the subject.

[0261] The disclosed methods can also be performed using a computer processing system adapted or configured to perform the methods for identifying any repeat expansion. One embodiment provides a computer processing system adapted or configured to perform the methods described herein. In one embodiment, the apparatus includes a sequencing device adapted or configured to sequence at least a portion of the nucleic acid molecules in the sample to obtain the type of sequence information described elsewhere herein. The apparatus may also include components for processing the sample. Such components are described elsewhere herein.

[0262] The sequences or other data can be input into the computer or may be stored, either directly or indirectly, on a computer readable medium. In one embodiment, the computer system is directly coupled to a sequencing device that reads and / or analyzes the nucleic acid sequences from the sample. The sequences or other information from such tools are provided through an interface in the computer system. Alternatively, the sequences processed by the system are provided from a sequence storage source, such as a database or other repository. Once available to the processing device, the memory device or mass storage device buffers or stores the sequences of the nucleic acids, at least temporarily. In addition, the memory device may store a number of tags, such as various chromosomes or genomes. The memory may also store various routines and / or programs for analyzing the representation of the sequences or mapped data. Such programs / routines may include programs for performing statistical analysis, etc.

[0263] In one example, a user provides a sample to a sequencing device. Data is collected and / or analyzed by a sequencing device connected to a computer. Software on the computer enables the data collection and / or analysis. The data can be stored, displayed (via a monitor or other similar device), and / or transmitted to another location. The computer may be connected to the Internet, which is used to transmit the data to a handheld device utilized by a remote user (e.g., a physician, scientist, or analyst). It is understood that the data can be stored and / or analyzed prior to transmission. In some embodiments, raw data is collected and transmitted to a remote user or device that analyzes and / or stores the data. The transfer process can occur via storage on a computer readable medium, which can be transported (e.g., via mail) to the end user. The remote user can be in the same or a different geographic location, including, but not limited to, a building, a city, a state, a country, or a continent.

[0264] In some embodiments, the method also includes collecting data regarding the plurality of polynucleotide sequences (e.g., reads, tags, and / or reference chromosomal sequences) and transmitting the data to a computer or other computing system. For example, the computer can be connected to a laboratory device, such as a sample collection device, a nucleotide amplification device, a nucleotide sequencing device, or a hybridization device. The computer can then collect the applicable data collected by the laboratory device. The data can be stored on the computer at any step, such as during collection in real time, before, during or in connection with transmission, or after transmission. The data can be stored on a computer-readable medium that can be extracted from the computer. The collected or stored data can be transmitted from the computer to a remote location, for example, via a local network or a wide area network such as the Internet. At the remote location, various operations can be performed on the transmitted data, as described below.

[0265] Types of electronically formatted data that may be stored, transmitted, analyzed, and / or manipulated by the systems, devices, and methods disclosed herein include, among others: Reads obtained by sequencing the nucleic acid in a test sample Tags obtained by aligning reads to a reference genome or other reference sequence or sequences Reference genome or sequence Locus specification indicating locus identity, location, and structural read coverage Variant Genotype Sequence Graph Graph Pathway Graph alignment information Actual calls of repeat expansions Diagnosis (clinical condition related to the call) Recommendations for further testing derived from the call and / or diagnosis Treatment and / or monitoring plans derived from the call and / or diagnosis

[0266] These various types of data may be acquired, stored, transmitted, analyzed, and / or manipulated at one or more locations using separate devices. Processing options span a broad spectrum. At one end of the spectrum, all or much of this information is stored and used at the location where the test sample is processed, such as a doctor's office or other clinical setting. At the other extreme, samples are acquired at one location, processed and optionally sequenced at a different location, reads are aligned, calls are made at one or more different locations, and a diagnosis, recommendation, and / or plan is prepared at yet another location (which may be the location where the sample was obtained).

[0267] In various embodiments, reads are generated on a sequencing device and then sent to a remote site where they are processed to generate repeat extension calls. At this remote location, by way of example, the reads are aligned to a reference sequence to generate anchor reads and anchored reads. Processing operations that may be employed at the separate locations include, among others: Sample collection Sample processing preliminary to sequencing Analyze sequence data and derive repeat extension calls diagnosis Implement a plan to report the diagnosis and / or call to the patient or healthcare provider Develop a plan for further treatment, testing, and / or monitoring counseling

[0268] Any one or more of these operations may be automated as described elsewhere herein. Typically, the sequencing and analysis of sequence data and the derivation of repeat extension calls may be performed computationally. Other operations may be performed manually or automatically.

[0269] Figure 6 shows one embodiment of a distributed system for generating a call or diagnosis from a test sample. A sample collection location 01 is used to collect a test sample from a patient. The sample is then provided to a processing and sequencing location 03, where the test sample can be processed and sequenced as described above. Location 03 includes equipment for processing the sample as well as equipment for sequencing the processed sample. The results of sequencing as described elsewhere herein are typically provided in an electronic format and are a collection of reads provided to a network such as the internet, as indicated by reference numeral 05 in Figure 6.

[0270] The sequence data is provided to a remote location 07 where analysis and call generation is performed. This location may include one or more powerful computing devices such as a computer or processor. After the computing resources at location 07 complete their analysis and generate a call from the received sequence information, the call is relayed back to the network 05. In some embodiments, not only is a call generated at location 07, but an associated diagnosis is also generated. The call and / or diagnosis is then transmitted across the network back to the sample collection location 01, as shown in FIG. 6. As will be described, this is one of many variations in how the various operations associated with generating a call or diagnosis can be split between various locations. One common variant includes providing sample collection as well as processing and sequencing at a single location. Another variant includes providing processing and sequencing at the same location as the analysis and call generation. experiment EXAMPLES

[0271] We applied the program to a simulated dataset containing a wide range of CAG and CCG repeat sizes in the HTT locus. HTT or Huntingtin is a disease gene associated with Huntington's disease (HD), a neurodegenerative disorder characterized by loss of striatal neurons. It is thought to be caused by an expanded, unstable trinucleotide repeat in the Huntingtin gene, which translates as a polyglutamine repeat in the protein product. A fairly wide range of trinucleotide repeats (9-35) has been identified in normal controls, with repeat numbers above 40 described as abnormal.

[0272] As expected, the accuracy obtained using the methods according to some embodiments was substantially higher when aligned to a sequence graph containing both repeats compared to when both repeats were analyzed independently. Similar improvements were observed compared to other STR genotypes (Figure 7).

[0273] To demonstrate that embodiments can genotype degenerate DNA repeats, we analyzed polyalanine repeats in the PHOX2B gene in 150 healthy controls and one sample carrying a known pathogenic expansion. PHOX2B contains a 20-codon polyalanine repeat that can expand to cause congenital central hypoventilation syndrome. Consistent with what is known about this repeat (Amiel et al. 2003), all but a few controls were genotyped as 20 / 20. Embodiments accurately genotype the only sample with the expansion as 20 / 27. The accuracy of this genotype was confirmed by Sanger sequencing. Embodiments also accurately detected a pathogenic SNV adjacent to an adenosine homopolymer in the MSH2 gene in three WGS replicates of a sample obtained from SeraCare Life Sciences (see Supplementary Materials).

[0274] In summary, we have developed a novel method that addresses the need for more accurate genotyping of complex loci. The method is able to genotype polyalanine repeats and resolve difficult regions containing small variants and repeats in close proximity to other repeats. We expect that the flexibility of the currently implemented sequence graph framework may enable a variety of novel variant calling applications. Analysis of CAG and CCG STRs in the HTT locus

[0275] We used wgsim(Li,nd) to simulate short-read samples for each combination of CAG and CCG repeat genotypes. We set the read length to 150, the distance between mate ends to 350, the standard deviation for the distance between mate ends to 50, the mutation rate and base error rate to 0.0010, and the fraction of indels to 0. The number of pairs was set to obtain a 40x probability of the locus. Reads were aligned to the GRCh37 reference using BWA-MEM 0.7.17-r1194-dirty (LL2013).

[0276] These data were analyzed in two ways in some embodiments. First, we analyzed the expression (CAG) * CAACAG (CCG) * We used GangSTR to identify the structure of the HTT locus and ensure that the reads are aligned to a sequence graph that includes both repeats. We then use several embodiments to analyze each repeat independently. In this mode, we aligned the reads to a graph representing the CAG STR and separately to a graph representing the CCG STR. Finally, we analyzed both reads independently using the latest version of GangSTR and TredParse, which aligns the reads to the repeat regions without using a sequence graph (Figure 7).

[0277] FIG. 7 shows the accuracy of genotyping CAG and CCG STRs at the HTT locus. (a) Performance of an embodiment when reads are aligned to a sequence graph that includes both repeats, (b) Performance of an embodiment when repeats are analyzed independently, (c) Performance of GangSTR, (d) Performance of TredParse. The maximum percentage deviation of the predicted STR length from the expected STR length was measured for each simulated sample. The blue dotted line corresponds to the genotype in the reference genome, and the red solid line represents the threshold for pathogenic extensions. The embodiment accurately predicts the appropriate genotype for all samples when both repeats are genotyped together. Joint genotyping offers a high advantage over separate genotyping of both reads with any of the three tools, which showed a high relative error rate, especially when one of the repeats is significantly longer than the other. Dataset

[0278] The PCR-free WGS sequencing data for 150 unrelated controls used for the analysis of PHOX2B polyalanine repeats are the Polaris Diversity Cohort, which consists of samples selected from the International Genome Sample Resource (1000 Genomes Project Consortium et al. 2015) (www|.|internationalgenome|.|org / ). WGS data can be obtained from the European Genome-phenome Archive (EGA; www|.|ebi|.|ac|.|uk / ega / home; PRJEB20654) and the NCBI Sequence Read Archive (SRA; www|.|ncbi|.|nlm|.|nih|.|gov / sra; bioproject:387148). Sample description (github||com / Illumina / Polaris / wiki / HiSeqX Diversity-Cohort).

[0279] A sample carrying the 20 / 27 expansion in PHOX2B was obtained from Genetics Laboratories Molecular Genetics, Addenbrooke's Treatment Centre, and Cambridge University.

[0280] SeraCare Life Sciences' sample, Seraseq Inherited Cancer DNA Mix v1, contains variants known to be both pathogenic and hard to call. The variants have all been synthetically spiked into the well-characterized cell line GM24385, which has an expected variant frequency of 50%. One of these engineered mutations corresponds to an SNV in the MSH2 gene directly adjacent to a long homopolymeric A tract.

[0281] Three replicates of SeraCare samples were prepared using Illumina's TruSeq PCR-free kit. The replicates were run on a single lane of a NovaSeq6000 and sequenced with a read length of 2 × 151 using the XP workflow. The replicates were analyzed using the 'Sentieon DNASeq FASTQ to VCF' and 'Whole Genome Requencing v8.0.0' Basespace apps (https: / / basespace.illumina.com). Sentieon can be considered a proxy for the variant calling performance of Broad's GATK software suite as Sentieon. None of the software solutions were able to accurately identify the MSH2 SNV. Fastq files and analysis results are provided via Basespace: https: / / basespace.illumina.com / s / HAQNxJyEtJLP.

[0282] The present disclosure may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the present disclosure is therefore indicated by the appended claims rather than the foregoing description. All changes that come within the meaning and range of equivalency of the claims are to be embraced within their scope.

Claims

1. 1. A method implemented using a computer comprising one or more processors and a system memory for genotyping a genomic locus comprising two or more repeat sequences, each of the two or more repeat subsequences comprising: (a) collecting paired-end sequence reads for a test sample from a database using the one or more processors; (b) aligning the sequence reads to a reference genome to determine genomic coordinates of the sequence reads and selecting a subset of the sequence reads; (c) aligning, by the one or more processors, the selected subset of sequence reads to the two or more repeat sequences represented by a sequence graph representing the genomic loci, the sequence graph having a directed graph data structure with vertices representing nucleic acid sequences and directed edges connecting the vertices, the sequence graph including two or more self-loops, each self-loop representing a repetitive subsequence, each repetitive subsequence including repeats of a different repeat unit of one or more nucleotides; (d) determining, by the one or more processors, one or more genotypes for the two or more repeat sequences using the sequence reads aligned to the one or more repeat sequences.

2. 2. The method of claim 1, wherein one of the two or more repeat sequences comprises a specific repeat unit that includes at least one incompletely specified nucleotide.

3. The method of claim 2 , wherein the particular repeating unit comprises a degenerate codon.

4. The method of any one of claims 1 to 3, wherein the sequence graph further comprises two or more alternative pathways for two or more alleles.

5. 5. The method of claim 4, wherein the two or more alleles comprise an indel or a substitution.

6. 6. The method of claim 5, wherein the substitution comprises a single nucleotide variant (SNV) or a single nucleotide polymorphism (SNP).

7. 5. The method of claim 4, further comprising genotyping the two or more alleles using sequence reads aligned to the two or more alternative pathways.

8. 8. The method of claim 7, wherein genotyping the two or more alleles comprises providing coverage of the two or more alternative pathways to a probabilistic model to determine probabilities of the two or more alleles.

9. 9. The method of claim 8, wherein the probability model simulates the probability of the allele as a function of the coverage of the allele, the function being selected from a Poisson distribution, a negative binomial distribution, a binomial distribution, or a beta binomial distribution.

10. 10. The method of claim 9, wherein the rate parameters of the Poisson distribution are estimated from read lengths and average depths observed at genomic loci.

11. 11. The method of any one of claims 1 to 10, wherein the subset of sequence reads comprises reads that are aligned to or near a region represented by a sequence graph.

12. The method of any one of claims 1 to 10, wherein the subset of sequence reads comprises unaligned reads that bind maps at or near a region represented by a sequence graph.

13. 11. The method of any one of claims 1 to 10, wherein the subset of sequence reads comprises reads that align to one or more off-target regions that are known hotspots for mismatching reads.

14. aligning sequence reads to the sequence graph, finding kmer matches between said sequence reads and paths in the sequence graph; Extending the kmer matches to perfect alignments of nodes and edges of the sequence graph that contain one or more self-loops.

15. The method of any one of claims 1 to 14, wherein aligning sequence reads to the sequence graph comprises graph reduction by removing low-reliability ends of the alignment.

16. aligning sequence reads to the sequence graph, aligning partial sequences of the reads into a sequence graph; 16. The method of any one of claims 1 to 15, comprising merging alignments of the partial sequences to form a complete alignment of the sequence reads.

17. The method of any one of claims 1 to 16, further comprising generating the sequence graph based on a locus specification comprising a locus structure of the genomic locus.

18. the sequence reads include paired-end reads, and operation (c) further comprises: (i) identifying an anchor read and an anchored read in the paired-end reads, wherein the anchor read is a read that aligns to or is aligned near the one or more repeat sequences, and the anchored read is a non-aligned read paired with the anchor read; (ii) determining the one or more genotypes for the one or more repetitive sequences using at least the anchored reads.

19. 20. The method of claim 18, wherein operation (ii) comprises determining the one or more genotypes for the one or more repeat sequences using the anchored reads and the anchored reads.

20. 20. The method of claim 18 or 19, wherein the anchored reads are aligned within a 5 kb repeat sequence.

21. 21. The method of any one of claims 18 to 20, wherein the unaligned reads comprise reads that cannot be aligned to the sequence graph or that align poorly to the sequence graph.

22. The method of any one of claims 1 to 21, wherein the one or more repeat sequences comprise a short tandem repeat (STR) sequence.

23. 23. The method of claim 22, wherein the STR expansion is associated with Fragile X syndrome, amyotrophic lateral sclerosis (ALS), Huntington's disease, Friedreich's ataxia, spinocerebellar degeneration, spinal-bulbar muscular atrophy, myotonic dystrophy, Machado-Joseph disease, or dentatorubral-pallidoluysian atrophy.

24. 24. The method of any one of claims 1 to 23, further comprising using a sequencer to generate paired-end reads from the test sample.

25. 25. The method of any one of claims 1 to 24, further comprising extracting the test sample from an individual.

26. The method of any one of claims 1 to 25, wherein the test sample is a blood sample, a urine sample, a saliva sample, or a tissue sample.

27. 27. The method of any one of claims 1 to 26, wherein the repeat unit comprises 1 to 50 nucleotides.

28. 28. The method of any one of claims 1 to 27, wherein the read is shorter than at least one of the one or more repetitive sequences.

29. 1. A system comprising: System memory; One or more processors, (a) collecting paired-end sequence reads for a test sample from a database; (b) aligning the sequence reads to a reference genome to determine genomic coordinates of the sequence reads and selecting a subset of the sequence reads; (c) aligning the selected subset of sequence reads to two or more repeat sequences represented by a sequence graph, the sequence graph having a directed graph data structure with vertices representing nucleic acid sequences and directed edges connecting the vertices, the sequence graph including two or more self-loops, each self-loop representing a repeat subsequence, each repeat subsequence including repeats of a different repeat unit of one or more nucleotides; (d) a processor configured to determine one or more genotypes for the two or more repeat sequences using the sequence reads aligned to the two or more repeat sequences.

30. 1. A computer program product having recorded thereon the computer program product comprising a non-transitory machine-readable medium having program code stored thereon, the program code, when executed by one or more processors of a computer system, causing the computer system to perform a method for genotyping genomic loci comprising two or more repeat sequences in a test sample comprising nucleic acid, the program code comprising: (a) code for collecting paired-end sequence reads for a test sample from a database; (b) aligning the sequence reads to a reference genome to determine genomic coordinates of the sequence reads and selecting a subset of the sequence reads; (c) code for aligning the selected subset of sequence reads to the two or more repeat sequences represented by a sequence graph, the sequence graph having a directed graph data structure with vertices representing nucleic acid sequences and directed edges connecting the vertices, the sequence graph including two or more self-loops, each self-loop representing a repeat subsequence, each repeat subsequence including repeats of a different repeat unit of one or more nucleotides; and (d) code for determining one or more genotypes for the two or more repeat sequences using the sequence reads aligned to the two or more repeat sequences.

Citation Information

Patent Citations

  • Methods and systems for aligning sequences in the presence of repeating elements

    US20150199474A1

  • Detecting repeat expansions with short read sequencing data

    WO2016038220A1